


<OAI-PMH xmlns="http://www.openarchives.org/OAI/2.0/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
         xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd">
    <responseDate>2025-09-09T14:05:44Z</responseDate>
    <request verb="GetRecord" identifier="oai:pubmedcentral.nih.gov:12405301" metadataPrefix="pmc">https://pmc.ncbi.nlm.nih.gov/api/oai/v1/mh/</request>
    
    <GetRecord>
        <record>
    <header>
    <identifier>oai:pubmedcentral.nih.gov:12405301</identifier>
    <datestamp>2025-09-04</datestamp>
    
        
        <setSpec>pmc-open</setSpec>
        
    
</header>
    <metadata>
        
        <article xmlns="https://jats.nlm.nih.gov/ns/archiving/1.4/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xsi:schemaLocation="https://jats.nlm.nih.gov/ns/archiving/1.4/ https://jats.nlm.nih.gov/archiving/1.4/xsd/JATS-archivearticle1-4.xsd" article-type="research-article" xml:lang="en" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">World J Urol</journal-id><journal-id journal-id-type="iso-abbrev">World J Urol</journal-id><journal-id journal-id-type="pmc-domain-id">365</journal-id><journal-id journal-id-type="pmc-domain">springeropen</journal-id><journal-title-group><journal-title>World Journal of Urology</journal-title></journal-title-group><issn pub-type="ppub">0724-4983</issn><issn pub-type="epub">1433-8726</issn><custom-meta-group><custom-meta><meta-name>pmc-is-collection-domain</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-collection-title</meta-name><meta-value>Springer</meta-value></custom-meta></custom-meta-group></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC12405301</article-id><article-id pub-id-type="pmcid-ver">PMC12405301.1</article-id><article-id pub-id-type="pmcaid">12405301</article-id><article-id pub-id-type="pmcaiid">12405301</article-id><article-id pub-id-type="pmid">40897892</article-id><article-id pub-id-type="doi">10.1007/s00345-025-05882-0</article-id><article-id pub-id-type="publisher-id">5882</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Research</subject></subj-group></article-categories><title-group><article-title>Radical nephroureterectomy vs kidney sparing surgery for upper tract urothelial carcinoma in solitary kidney patients: a multi-institutional analysis of the ROBUUST 2.0 registry</article-title></title-group><contrib-group><contrib contrib-type="author"><name name-style="western"><surname>Ditonno</surname><given-names initials="F">Francesco</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Veccia</surname><given-names initials="A">Alessandro</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Bignante</surname><given-names initials="G">Gabriele</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Wu</surname><given-names initials="Z">Zhenjie</given-names></name><xref ref-type="aff" rid="Aff3">3</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Wang</surname><given-names initials="L">Linhui</given-names></name><xref ref-type="aff" rid="Aff3">3</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Abdollah</surname><given-names initials="F">Firas</given-names></name><xref ref-type="aff" rid="Aff4">4</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Stephens</surname><given-names initials="A">Alex</given-names></name><xref ref-type="aff" rid="Aff4">4</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Simone</surname><given-names initials="G">Giuseppe</given-names></name><xref ref-type="aff" rid="Aff5">5</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Tuderti</surname><given-names initials="G">Gabriele</given-names></name><xref ref-type="aff" rid="Aff5">5</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Lee</surname><given-names initials="R">Randall</given-names></name><xref ref-type="aff" rid="Aff6">6</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Eun</surname><given-names initials="DD">Daniel D.</given-names></name><xref ref-type="aff" rid="Aff6">6</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Correa</surname><given-names initials="AF">Andres F.</given-names></name><xref ref-type="aff" rid="Aff6">6</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>De Cobelli</surname><given-names initials="O">Ottavio</given-names></name><xref ref-type="aff" rid="Aff7">7</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Ferro</surname><given-names initials="M">Matteo</given-names></name><xref ref-type="aff" rid="Aff7">7</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Porpiglia</surname><given-names initials="F">Francesco</given-names></name><xref ref-type="aff" rid="Aff8">8</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Amparore</surname><given-names initials="D">Daniele</given-names></name><xref ref-type="aff" rid="Aff8">8</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Checcucci</surname><given-names initials="E">Enrico</given-names></name><xref ref-type="aff" rid="Aff9">9</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Tufano</surname><given-names initials="A">Antonio</given-names></name><xref ref-type="aff" rid="Aff10">10</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Contieri</surname><given-names initials="R">Roberto</given-names></name><xref ref-type="aff" rid="Aff10">10</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Perdon&#224;</surname><given-names initials="S">Sisto</given-names></name><xref ref-type="aff" rid="Aff10">10</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Bhanvadia</surname><given-names initials="R">Raj</given-names></name><xref ref-type="aff" rid="Aff11">11</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Margulis</surname><given-names initials="V">Vitaly</given-names></name><xref ref-type="aff" rid="Aff11">11</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Br&#246;nimann</surname><given-names initials="S">Stephan</given-names></name><xref ref-type="aff" rid="Aff12">12</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Singla</surname><given-names initials="N">Nirmish</given-names></name><xref ref-type="aff" rid="Aff12">12</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Porter</surname><given-names initials="J">James</given-names></name><xref ref-type="aff" rid="Aff13">13</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Ghodoussipour</surname><given-names initials="S">Saum</given-names></name><xref ref-type="aff" rid="Aff14">14</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Minervini</surname><given-names initials="A">Andrea</given-names></name><xref ref-type="aff" rid="Aff15">15</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Mari</surname><given-names initials="A">Andrea</given-names></name><xref ref-type="aff" rid="Aff15">15</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Lambertini</surname><given-names initials="L">Luca</given-names></name><xref ref-type="aff" rid="Aff15">15</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Ghoreifi</surname><given-names initials="A">Alireza</given-names></name><xref ref-type="aff" rid="Aff16">16</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Nativ</surname><given-names initials="OF">Omri Falik</given-names></name><xref ref-type="aff" rid="Aff17">17</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Gonzalgo</surname><given-names initials="ML">Mark L.</given-names></name><xref ref-type="aff" rid="Aff17">17</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Sidhom</surname><given-names initials="D">Daniel</given-names></name><xref ref-type="aff" rid="Aff18">18</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Sundaram</surname><given-names initials="CP">Chandru P.</given-names></name><xref ref-type="aff" rid="Aff18">18</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Ben-David</surname><given-names initials="R">Reuben</given-names></name><xref ref-type="aff" rid="Aff19">19</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Eraky</surname><given-names initials="A">Ahmed</given-names></name><xref ref-type="aff" rid="Aff19">19</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Mehrazin</surname><given-names initials="R">Reza</given-names></name><xref ref-type="aff" rid="Aff19">19</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Yoshida</surname><given-names initials="T">Takashi</given-names></name><xref ref-type="aff" rid="Aff20">20</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Kinoshita</surname><given-names initials="H">Hidefumi</given-names></name><xref ref-type="aff" rid="Aff20">20</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Dehghanmanshadi</surname><given-names initials="A">Alireza</given-names></name><xref ref-type="aff" rid="Aff21">21</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Rais-Bahrami</surname><given-names initials="S">Soroush</given-names></name><xref ref-type="aff" rid="Aff21">21</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Meagher</surname><given-names initials="MF">Margaret F.</given-names></name><xref ref-type="aff" rid="Aff22">22</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Puri</surname><given-names initials="D">Dhruv</given-names></name><xref ref-type="aff" rid="Aff22">22</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Derweesh</surname><given-names initials="IH">Ithaar H.</given-names></name><xref ref-type="aff" rid="Aff22">22</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Moghaddam</surname><given-names initials="FS">Farshad S.</given-names></name><xref ref-type="aff" rid="Aff23">23</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Djaladat</surname><given-names initials="H">Hooman</given-names></name><xref ref-type="aff" rid="Aff23">23</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Bertolo</surname><given-names initials="R">Riccardo</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Autorino</surname><given-names initials="R">Riccardo</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author" corresp="yes"><name name-style="western"><surname>Antonelli</surname><given-names initials="A">Alessandro</given-names></name><address><email>alessandro_antonelli@me.com</email><email>alessandro.antonelli@univr.it</email></address><xref ref-type="aff" rid="Aff1">1</xref></contrib><aff id="Aff1"><label>1</label>Department of Urology, Azienda Ospedaliera Universitaria Integrata Verona, University of Verona, Verona, 37126 Italy </aff><aff id="Aff2"><label>2</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/01k9xac83</institution-id><institution-id institution-id-type="GRID">grid.262743.6</institution-id><institution-id institution-id-type="ISNI">0000 0001 0705 8297</institution-id><institution>Department of Urology, </institution><institution>Rush University, </institution></institution-wrap>Chicago, IL USA </aff><aff id="Aff3"><label>3</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/02bjs0p66</institution-id><institution-id institution-id-type="GRID">grid.411525.6</institution-id><institution-id institution-id-type="ISNI">0000 0004 0369 1599</institution-id><institution>Department of Urology, </institution><institution>Shanghai Changhai Hospital, Naval Medical University, </institution></institution-wrap>Shanghai, China </aff><aff id="Aff4"><label>4</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/0193sb042</institution-id><institution-id institution-id-type="GRID">grid.413103.4</institution-id><institution-id institution-id-type="ISNI">0000 0001 2160 8953</institution-id><institution>Henry Ford Hospital, Vattikuti Urology Institute, </institution></institution-wrap>Detroit, MI USA </aff><aff id="Aff5"><label>5</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/04j6jb515</institution-id><institution-id institution-id-type="GRID">grid.417520.5</institution-id><institution-id institution-id-type="ISNI">0000 0004 1760 5276</institution-id><institution>Department of Urology, </institution><institution>IRCCS Regina Elena National Cancer Institute, </institution></institution-wrap>Rome, Italy </aff><aff id="Aff6"><label>6</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/0567t7073</institution-id><institution-id institution-id-type="GRID">grid.249335.a</institution-id><institution-id institution-id-type="ISNI">0000 0001 2218 7820</institution-id><institution>Department of Urology, </institution><institution>Fox Chase Cancer Center, </institution></institution-wrap>Philadelphia, PA USA </aff><aff id="Aff7"><label>7</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/02vr0ne26</institution-id><institution-id institution-id-type="GRID">grid.15667.33</institution-id><institution-id institution-id-type="ISNI">0000 0004 1757 0843</institution-id><institution>Division of Urology, </institution><institution>European Institute of Oncology IRCCS, </institution></institution-wrap>Milan, Italy </aff><aff id="Aff8"><label>8</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/048tbm396</institution-id><institution-id institution-id-type="GRID">grid.7605.4</institution-id><institution-id institution-id-type="ISNI">0000 0001 2336 6580</institution-id><institution>Division of Urology, </institution><institution>University of Turin San Luigi Gonzaga Hospital, </institution></institution-wrap>Turin, Italy </aff><aff id="Aff9"><label>9</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/04wadq306</institution-id><institution-id institution-id-type="GRID">grid.419555.9</institution-id><institution-id institution-id-type="ISNI">0000 0004 1759 7675</institution-id><institution>Department of Surgery, </institution><institution>Candiolo Cancer Institute, FPO-IRCCS, </institution></institution-wrap>Candiolo, Turin, Italy </aff><aff id="Aff10"><label>10</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/0506y2b23</institution-id><institution-id institution-id-type="GRID">grid.508451.d</institution-id><institution-id institution-id-type="ISNI">0000 0004 1760 8805</institution-id><institution>Department of Urology, </institution><institution>Istituto Nazionale Tumori IRCCS Fondazione G. Pascale, </institution></institution-wrap>Naples, Italy </aff><aff id="Aff11"><label>11</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/05byvp690</institution-id><institution-id institution-id-type="GRID">grid.267313.2</institution-id><institution-id institution-id-type="ISNI">0000 0000 9482 7121</institution-id><institution>Department of Urology, </institution><institution>University of Texas Southwestern Medical Center, </institution></institution-wrap>Dallas, TX USA </aff><aff id="Aff12"><label>12</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/00za53h95</institution-id><institution-id institution-id-type="GRID">grid.21107.35</institution-id><institution-id institution-id-type="ISNI">0000 0001 2171 9311</institution-id><institution>John Hopkins University, The James Buchanan Brady Urological Institute, </institution></institution-wrap>Baltimore, MD USA </aff><aff id="Aff13"><label>13</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/004jktf35</institution-id><institution-id institution-id-type="GRID">grid.281044.b</institution-id><institution-id institution-id-type="ISNI">0000 0004 0463 5388</institution-id><institution>Swedish Medical Center, </institution></institution-wrap>Seattle, WA USA </aff><aff id="Aff14"><label>14</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/0060x3y55</institution-id><institution-id institution-id-type="ISNI">0000 0004 0405 0718</institution-id><institution>Section of Urologic Oncology, </institution><institution>Rutgers Cancer Institute and Rutgers Robert Wood Johnson Medical School, </institution></institution-wrap>New Brunswick, NJ USA </aff><aff id="Aff15"><label>15</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/04jr1s763</institution-id><institution-id institution-id-type="GRID">grid.8404.8</institution-id><institution-id institution-id-type="ISNI">0000 0004 1757 2304</institution-id><institution>Oncologic Minimally Invasive Urology and Andrology Unit, Careggi Hospital, </institution><institution>University of Florence, </institution></institution-wrap>Florence, Italy </aff><aff id="Aff16"><label>16</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/00py81415</institution-id><institution-id institution-id-type="GRID">grid.26009.3d</institution-id><institution-id institution-id-type="ISNI">0000 0004 1936 7961</institution-id><institution>Department of Urology, </institution><institution>Duke University, </institution></institution-wrap>Durham, NC USA </aff><aff id="Aff17"><label>17</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/02dgjyy92</institution-id><institution-id institution-id-type="GRID">grid.26790.3a</institution-id><institution-id institution-id-type="ISNI">0000 0004 1936 8606</institution-id><institution>University of Miami Miller School of Medicine, Desai Sethi Urology Institute, </institution></institution-wrap>Miami, FL USA </aff><aff id="Aff18"><label>18</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/05gxnyn08</institution-id><institution-id institution-id-type="GRID">grid.257413.6</institution-id><institution-id institution-id-type="ISNI">0000 0001 2287 3919</institution-id><institution>Department of Urology, </institution><institution>Indiana University, </institution></institution-wrap>Indianapolis, IN USA </aff><aff id="Aff19"><label>19</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/04a9tmd77</institution-id><institution-id institution-id-type="GRID">grid.59734.3c</institution-id><institution-id institution-id-type="ISNI">0000 0001 0670 2351</institution-id><institution>Department of Urology, </institution><institution>Icahn School of Medicine at Mount Sinai Hospital, </institution></institution-wrap>New York, NY USA </aff><aff id="Aff20"><label>20</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/001xjdh50</institution-id><institution-id institution-id-type="GRID">grid.410783.9</institution-id><institution-id institution-id-type="ISNI">0000 0001 2172 5041</institution-id><institution>Kansai Medical University, </institution></institution-wrap>Osaka, Japan </aff><aff id="Aff21"><label>21</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/008s83205</institution-id><institution-id institution-id-type="GRID">grid.265892.2</institution-id><institution-id institution-id-type="ISNI">0000 0001 0634 4187</institution-id><institution>Department of Urology, </institution><institution>University of Alabama at Birmingham, Heersink School of Medicine, </institution></institution-wrap>Birmingham, AL USA </aff><aff id="Aff22"><label>22</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/0168r3w48</institution-id><institution-id institution-id-type="GRID">grid.266100.3</institution-id><institution-id institution-id-type="ISNI">0000 0001 2107 4242</institution-id><institution>Department of Urology, </institution><institution>UC San Diego School of Medicine, </institution></institution-wrap>La Jolla, San Diego, CA USA </aff><aff id="Aff23"><label>23</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/03taz7m60</institution-id><institution-id institution-id-type="GRID">grid.42505.36</institution-id><institution-id institution-id-type="ISNI">0000 0001 2156 6853</institution-id><institution>Norris Comprehensive Cancer Center, Institute of Urology, </institution><institution>University of Southern California, </institution></institution-wrap>Los Angeles, CA USA </aff></contrib-group><pub-date pub-type="epub"><day>3</day><month>9</month><year>2025</year></pub-date><pub-date pub-type="ppub"><year>2025</year></pub-date><volume>43</volume><issue>1</issue><issue-id pub-id-type="pmc-issue-id">496088</issue-id><elocation-id>534</elocation-id><history><date date-type="received"><day>24</day><month>2</month><year>2025</year></date><date date-type="accepted"><day>8</day><month>8</month><year>2025</year></date></history><pub-history><event event-type="pmc-release"><date><day>03</day><month>09</month><year>2025</year></date></event><event event-type="pmc-live"><date><day>04</day><month>09</month><year>2025</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2025-09-04 00:25:59.930"><day>04</day><month>09</month><year>2025</year></date></event></pub-history><permissions><copyright-statement>&#169; The Author(s) 2025</copyright-statement><copyright-year>2025</copyright-year><license><ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p><bold>Open Access</bold> This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article&#8217;s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article&#8217;s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>.</license-p></license></permissions><self-uri content-type="pmc-pdf" xlink:href="345_2025_Article_5882.pdf"/><abstract id="Abs1"><sec><title>Purpose</title><p id="Par1">Radical nephroureterectomy (RNU) for upper tract urothelial carcinoma (UTUC) in solitary kidney patients is a rare and underreported scenario. This study aims to compare the outcomes of UTUC solitary kidney patients becoming anephric after RNU to those of patients undergoing kidney-sparing surgery (KSS).</p></sec><sec><title>Methods</title><p id="Par2">Data from patients with a solitary kidney were retrieved from the ROBUUST 2.0 database, a global, multicenter registry containing data on patients who underwent curative surgery for UTUC. Baseline patient demographics, disease characteristics, and surgical features were compared between RNU and KSS. Kaplan-Meier methods were used to estimate recurrence-free survival (RFS), metastasis-free survival (MFS), cancer-specific survival (CSS), and overall survival (OS) in patients undergoing RNU, with 3-year and 5-year cutoffs applied.</p></sec><sec><title>Results</title><p id="Par3">Thirty-nine patients (76.5%) underwent RNU, whereas 12 (23.5%) underwent KSS. Despite a comparable preoperative renal function, the distribution of CKD stages differed significantly between the groups (<italic toggle="yes">p</italic>&#8201;=&#8201;0.019). Despite a similar rate of postoperative complications, patients undergoing RNU experienced a significantly higher median LOS (<italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.001). Among RNU patients, OS was 83.9%, CSS was 96.9%, RFS was 71.8%, and MFS was 84.4% at the 3-year follow-up. After 5 years post-surgery, OS was 73.4%, CSS was 83.1%, RFS was 59.9%, and MFS was 78.5% in the same cohort.</p></sec><sec><title>Conclusions</title><p id="Par4">UTUC solitary kidney patients undergoing RNU or KSS face a substantial perioperative burden. Despite these challenges, our cohort demonstrated favorable oncological outcomes comparable to those reported in the existing literature.</p></sec><sec><title>Supplementary Information</title><p>The online version contains supplementary material available at 10.1007/s00345-025-05882-0.</p></sec></abstract><kwd-group xml:lang="en"><title>Keywords</title><kwd>Postoperative complications</kwd><kwd>Radical nephroureterectomy</kwd><kwd>Renal insufficiency</kwd><kwd>Solitary kidney</kwd><kwd>Upper tract urothelial carcinoma</kwd></kwd-group><funding-group><award-group><funding-source><institution>Universit&#224; degli Studi di Verona</institution></funding-source></award-group><open-access><p>Open access funding provided by Universit&#224; degli Studi di Verona within the CRUI-CARE Agreement.</p></open-access></funding-group><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#169; Springer-Verlag GmbH Germany, part of Springer Nature 2025</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="Sec1"><title>Introduction</title><p id="Par5">Patients with a solitary kidney represent a unique clinical scenario in which treatment decisions must carefully balance oncological outcomes with the preservation of renal function. KSS is a viable option for this subgroup, even in high-risk patients [<xref ref-type="bibr" rid="CR1">1</xref>]. Nevertheless, RNU may still be necessary for cases involving tumors not amenable to KSS or in patients with end-stage renal disease (ESRD), for whom the only alternative is often palliative treatment, including urinary diversion. Anephric status profoundly reduces the quality and quantity of life due to lifelong hemodialysis and fluid restrictions [<xref ref-type="bibr" rid="CR2">2</xref>]. Furthermore, UTUC aggressiveness limits the prospects for renal transplantation, making this approach an exceptional and seldom-adopted option.</p><p id="Par6">The present study reports the outcomes of solitary kidney patients undergoing RNU or KSS using a large multi-institutional dataset, offering insights and evidence to support clinical decision-making in this relatively uncommon scenario.</p></sec><sec id="Sec2"><title>Materials and methods</title><sec id="Sec3"><title>Study population</title><p id="Par7">The ROBUUST (ROBotic surgery for Upper tract Urothelial cancer STtudy) 2.0 is a global, multicenter registry collecting data on patients undergoing curative surgical interventions&#8212;RNU or KSS, including segmental ureterectomy and endoscopic ablation&#8212;for UTUC at participating institutions from 2015 to 2024. Ethical approval and data-sharing permissions were granted at all participating centers (<italic toggle="yes">IRB: 22111001</italic>). As per study protocol, patients underwent scheduled follow-up visits with quarterly urinary cytology and cystoscopy for the first two years, along with quarterly CT scans during the first year, followed by annual assessments thereafter. Additionally, endoscopic follow-up for patients undergoing KSS adhered to international guideline recommendations. All surgeries were performed by experienced urological surgeons at tertiary referral centers following standardized techniques. Data retrieval from the ROBUUST database was limited to solitary kidney patients undergoing either RNU or KSS, excluding those with incomplete data on relevant predictors.</p></sec><sec id="Sec4"><title>Study variables and outcomes</title><p id="Par8">Baseline demographics and disease features were recorded. Surgical variables included the adopted technique and approach, the execution of a single-stage technique and of a concomitant radical cystectomy, operative time (OT), estimated blood loss (EBL), bladder cuff management, lymph node dissection, type and grade of intraoperative and postoperative complications graded according to the standardized Clavien-Dindo (CD) classification [<xref ref-type="bibr" rid="CR3">3</xref>] (defined as major when grade was &#8805;&#8201;CD III), and length of stay (LOS). Additionally, a subanalysis by complication type was carried out to clarify the etiology of postoperative complications. Pathological features, such as tumor stage and grade, margin status, nodal stage, and lymph node yield were reported.</p><p id="Par9">Functional data (serum creatinine [SCr] and estimated glomerular filtration rate [eGFR]) were recorded before surgery, at the time of discharge, at 3 and 12 months postoperatively, and at the last recorded follow-up after surgery. The eGFR was calculated using the Chronic Kidney Disease Epidemiology Collaboration 2021 formula [<xref ref-type="bibr" rid="CR4">4</xref>].</p><p id="Par10">All-cause mortality was defined as death from any cause, while cancer-specific mortality referred to deaths directly attributed to cancer. Oncological time-to-event outcomes included recurrence-free survival (RFS), defined as the time from diagnosis to urothelial recurrence into the bladder or homolateral upper urinary tract; metastasis-free survival (MFS), defined as the time from diagnosis to distant metastasis; cancer-specific survival (CSS), and overall survival (OS), defined as the time from diagnosis to tumor-related death and death from any cause, respectively.</p></sec><sec id="Sec5"><title>Statistical analysis</title><p id="Par11">Statistical analyses followed established guidelines [<xref ref-type="bibr" rid="CR5">5</xref>, <xref ref-type="bibr" rid="CR6">6</xref>]. The cohort was divided into two groups according to treatment modality. Continuous variables were reported using median and interquartile ranges (IQR), while categorical variables were summarized using proportions and frequencies. Descriptive statistical analysis was carried out as appropriate. Variation in eGFR was calculated as the difference between the baseline and the last follow-up values. Kaplan-Meier methods were employed to calculate local RFS, distant MFS, CSS, and OS, with a 3-year and 5-year cutoff applied. To analyze oncological outcomes based on renal function and surgical approach (RNU vs. KSS), preplanned subanalyses stratifying survival data by chronic kidney disease (CKD) stage and treatment type were conducted, using the log-rank test to assess statistical differences between subgroups. Follow-up duration was calculated from treatment to recurrence or metastasis for RFS and MFS, and from treatment to death or last follow-up for CSS and OS. Statistical analyses were conducted using Stata<sup>&#174;</sup> v17.0 (StataCorp LLC, College Station, TX, USA), with statistical significance set at <italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.05.</p></sec></sec><sec id="Sec6"><title>Results</title><sec id="Sec7"><title>Baseline features</title><p id="Par12">In the overall cohort, 3,216 patients underwent surgical treatment for UTUC and were included in the dataset, of whom 51 (1.6%) had a solitary kidney before intervention. Among them, 39 (76.5%) underwent RNU, whereas the remaining patients (12, 23.5%) underwent KSS, including 10 segmental ureterectomies and two endoscopic ablations, with a median follow-up of 14 months (5&#8211;48). Baseline characteristics are summarized in Table&#160;<xref rid="Tab1" ref-type="table">1</xref>. The median (IQR) age of patients undergoing RNU was significantly higher (80 years, 76-81.5), compared to those undergoing KSS (70 years, 66&#8211;78, <italic toggle="yes">p</italic>&#8201;=&#8201;0.006). Despite the median preoperative SCr and eGFR being comparable between patients undergoing RNU and KSS, the distribution of CKD stages differed significantly between the groups (<italic toggle="yes">p</italic>&#8201;=&#8201;0.019). However, the remaining baseline features were comparable between the two subgroups. Namely, in the RNU subgroup, the renal pelvis (21, 53.9%) was the most common tumor site, compared to the ureteral tumors in the KSS subgroup (9, 75%), with no significant difference in terms of tumour site (<italic toggle="yes">p</italic>&#8201;=&#8201;0.051).</p><p id="Par13">
<table-wrap id="Tab1" position="float" orientation="portrait"><label>Table 1</label><caption><p>Baseline features of solitary kidney UTUC patients undergoing RNU vs. KSS</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" colspan="1" rowspan="1">Variables</th><th align="left" colspan="1" rowspan="1">RNU<break/>(<italic toggle="yes">n</italic>&#8201;=&#8201;39)</th><th align="left" colspan="1" rowspan="1">KSS*<break/>
<italic toggle="yes">(n&#8201;=&#8201;12)</italic>
</th><th align="left" colspan="1" rowspan="1"><italic toggle="yes">P</italic> value</th></tr></thead><tbody><tr><td align="left" colspan="1" rowspan="1">Age, median (IQR)</td><td align="left" colspan="1" rowspan="1">80 years (76-81.5)</td><td align="left" colspan="1" rowspan="1">70 years (66&#8211;78)</td><td align="left" colspan="1" rowspan="1">
<bold>0.006</bold>
</td></tr><tr><td align="left" colspan="1" rowspan="1">Sex, n (%)</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">&#160;Male</td><td align="left" colspan="1" rowspan="1">31 (79.5)</td><td align="left" colspan="1" rowspan="1">8 (66.7)</td><td align="left" colspan="1" rowspan="1">0.442</td></tr><tr><td align="left" colspan="1" rowspan="1">Ethnicity, n (%)</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">&#160;Caucasian</td><td align="left" colspan="1" rowspan="1">20 (51.3)</td><td align="left" colspan="1" rowspan="1">9 (75)</td><td align="left" colspan="1" rowspan="1">0.220</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;Black</td><td align="left" colspan="1" rowspan="1">2 (5.1)</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">&#160;Hispanic</td><td align="left" colspan="1" rowspan="1">2 (5.1)</td><td align="left" colspan="1" rowspan="1">1 (8.33)</td><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">&#160;Asian</td><td align="left" colspan="1" rowspan="1">14 (35.9)</td><td align="left" colspan="1" rowspan="1">1 (8.33)</td><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">&#160;Other</td><td align="left" colspan="1" rowspan="1">1 (2.6)</td><td align="left" colspan="1" rowspan="1">1 (8.33)</td><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">Smoke, n (%)</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">&#160;No</td><td align="left" colspan="1" rowspan="1">22 (56.4)</td><td align="left" colspan="1" rowspan="1">3 (25)</td><td align="left" colspan="1" rowspan="1">0.067</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;Former</td><td align="left" colspan="1" rowspan="1">11 (28.2)</td><td align="left" colspan="1" rowspan="1">8 (66.7)</td><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">BMI, median (IQR)</td><td align="left" colspan="1" rowspan="1">24.1&#160;kg/m<sup>2</sup> (22.6&#8211;30.1)</td><td align="left" colspan="1" rowspan="1">26.1&#160;kg/m<sup>2</sup> (23-31.1)</td><td align="left" colspan="1" rowspan="1">0.562</td></tr><tr><td align="left" colspan="1" rowspan="1">Hypertension, n (%)</td><td align="left" colspan="1" rowspan="1">22 (56.4)</td><td align="left" colspan="1" rowspan="1">10 (83.3)</td><td align="left" colspan="1" rowspan="1">0.171</td></tr><tr><td align="left" colspan="1" rowspan="1">Diabetes mellitus, n (%)</td><td align="left" colspan="1" rowspan="1">12 (30.8)</td><td align="left" colspan="1" rowspan="1">3 (25)</td><td align="left" colspan="1" rowspan="1">0.503</td></tr><tr><td align="left" colspan="1" rowspan="1">History of BC, n (%)</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">&#160;Low grade</td><td align="left" colspan="1" rowspan="1">10/37 (27)</td><td align="left" colspan="1" rowspan="1">0 (0)</td><td align="left" colspan="1" rowspan="1">0.09</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;High grade</td><td align="left" colspan="1" rowspan="1">7/37 (18.9)</td><td align="left" colspan="1" rowspan="1">3 (25)</td><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">Previous BC surgery, n (%)</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">&#160;TURB-T</td><td align="left" colspan="1" rowspan="1">14/37 (37.8)</td><td align="left" colspan="1" rowspan="1">3 (25)</td><td align="left" colspan="1" rowspan="1">1</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;Radical cystectomy</td><td align="left" colspan="1" rowspan="1">3 (8.1)</td><td align="left" colspan="1" rowspan="1">0</td><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">Symptoms, n (%)</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">&#160;Hematuria</td><td align="left" colspan="1" rowspan="1">21 (53.8)</td><td align="left" colspan="1" rowspan="1">7 (58.4)</td><td align="left" colspan="1" rowspan="1">0.227</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;Flank pain</td><td align="left" colspan="1" rowspan="1">2 (5.1)</td><td align="left" colspan="1" rowspan="1">0 (0)</td><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">&#160;Asymptomatic</td><td align="left" colspan="1" rowspan="1">7 (18)</td><td align="left" colspan="1" rowspan="1">4 (33.3)</td><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">&#160;Other/Unknown</td><td align="left" colspan="1" rowspan="1">9 (23.1)</td><td align="left" colspan="1" rowspan="1">1 (8.3)</td><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">Preop Cr, median (IQR)</td><td align="left" colspan="1" rowspan="1">1.45&#160;mg/dL (1.06&#8211;2.16)</td><td align="left" colspan="1" rowspan="1">1.37&#160;mg/dL (1.12&#8211;1.54)</td><td align="left" colspan="1" rowspan="1">0.377</td></tr><tr><td align="left" colspan="1" rowspan="1">Preop eGFR, median (IQR)</td><td align="left" colspan="1" rowspan="1">45.5 mL/min/1.73m<sup>2</sup> (28&#8211;56)</td><td align="left" colspan="1" rowspan="1">47 mL/min/1.73m<sup>2</sup> (43.9&#8211;59.5)</td><td align="left" colspan="1" rowspan="1">0.434</td></tr><tr><td align="left" colspan="1" rowspan="1">CKD stage, n (%)</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">&#160;0</td><td align="left" colspan="1" rowspan="1">4 (10.3)</td><td align="left" colspan="1" rowspan="1">1 (8.3)</td><td align="left" colspan="1" rowspan="1">
<bold>0.019</bold>
</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;I</td><td align="left" colspan="1" rowspan="1">5 (12.8)</td><td align="left" colspan="1" rowspan="1">3 (25)</td><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">&#160;II</td><td align="left" colspan="1" rowspan="1">6 (15.4)</td><td align="left" colspan="1" rowspan="1">1 (8.3)</td><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">&#160;III</td><td align="left" colspan="1" rowspan="1">14 (35.9)</td><td align="left" colspan="1" rowspan="1">7 (58.4)</td><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">&#160;IV</td><td align="left" colspan="1" rowspan="1">5 (12.8)</td><td align="left" colspan="1" rowspan="1">0 (0)</td><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">&#160;V</td><td align="left" colspan="1" rowspan="1">5 (12.8)</td><td align="left" colspan="1" rowspan="1">0 (0)</td><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">Tumor size, median (IQR)</td><td align="left" colspan="1" rowspan="1">2.5&#160;cm (2&#8211;4)</td><td align="left" colspan="1" rowspan="1">1.9&#160;cm (1.5-3)</td><td align="left" colspan="1" rowspan="1">0.172</td></tr><tr><td align="left" colspan="1" rowspan="1">Tumor site, n (%)</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">&#160;Pelvis</td><td align="left" colspan="1" rowspan="1">21 (53.9)</td><td align="left" colspan="1" rowspan="1">1 (8.3)</td><td align="left" colspan="1" rowspan="1">0.051</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;Calyx</td><td align="left" colspan="1" rowspan="1">3 (7.7)</td><td align="left" colspan="1" rowspan="1">1 (8.3)</td><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">&#160;UPJ</td><td align="left" colspan="1" rowspan="1">2 (5.1)</td><td align="left" colspan="1" rowspan="1">1 (8.4)</td><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">&#160;Ureter</td><td align="left" colspan="1" rowspan="1">11 (28.2)</td><td align="left" colspan="1" rowspan="1">9 (75)</td><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">&#160;Kidney and ureter</td><td align="left" colspan="1" rowspan="1">2 (5.1)</td><td align="left" colspan="1" rowspan="1">0 (0)</td><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">Multifocal, n (%)</td><td align="left" colspan="1" rowspan="1">10 (25.6)</td><td align="left" colspan="1" rowspan="1">6 (50)</td><td align="left" colspan="1" rowspan="1">0.157</td></tr><tr><td align="left" colspan="1" rowspan="1">Hydronephrosis, n (%)</td><td align="left" colspan="1" rowspan="1">18 (46.1)</td><td align="left" colspan="1" rowspan="1">4 (33.3)</td><td align="left" colspan="1" rowspan="1">0.511</td></tr><tr><td align="left" colspan="1" rowspan="1">Tumor stage, n (%)</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">&#160;cTa</td><td align="left" colspan="1" rowspan="1">8 (20.5)</td><td align="left" colspan="1" rowspan="1">9 (75)</td><td align="left" colspan="1" rowspan="1">
<bold>0.017</bold>
</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;cT1</td><td align="left" colspan="1" rowspan="1">14 (36)</td><td align="left" colspan="1" rowspan="1">1 (8.3)</td><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">&#160;cT2</td><td align="left" colspan="1" rowspan="1">7 (17.9)</td><td align="left" colspan="1" rowspan="1">1 (8.4)</td><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">&#160;cT3-4</td><td align="left" colspan="1" rowspan="1">7 (17.9)</td><td align="left" colspan="1" rowspan="1">0 (0)</td><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">&#160;Unknown</td><td align="left" colspan="1" rowspan="1">3 (7.7)</td><td align="left" colspan="1" rowspan="1">1 (8.3)</td><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">Nodal stage, n (%)</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">&#160;cN0</td><td align="left" colspan="1" rowspan="1">37 (94.8)</td><td align="left" colspan="1" rowspan="1">12 (100)</td><td align="left" colspan="1" rowspan="1">1</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;cN1</td><td align="left" colspan="1" rowspan="1">1 (2.6)</td><td align="left" colspan="1" rowspan="1">0 (0)</td><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">&#160;cN2</td><td align="left" colspan="1" rowspan="1">1 (2.6)</td><td align="left" colspan="1" rowspan="1">0 (0)</td><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">Metastatic disease, n (%)</td><td align="left" colspan="1" rowspan="1">1 (2.6)</td><td align="left" colspan="1" rowspan="1">1 (8.3)</td><td align="left" colspan="1" rowspan="1">0.434</td></tr><tr><td align="left" colspan="1" rowspan="1">Preoperative URS, n (%)</td><td align="left" colspan="1" rowspan="1">23 (59)</td><td align="left" colspan="1" rowspan="1">9 (75)</td><td align="left" colspan="1" rowspan="1">0.494</td></tr><tr><td align="left" colspan="1" rowspan="1">Biopsy grade, n (%)</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">&#160;Low grade</td><td align="left" colspan="1" rowspan="1">4/23 (17.4)</td><td align="left" colspan="1" rowspan="1">3/9 (33.3)</td><td align="left" colspan="1" rowspan="1">0.661</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;High grade</td><td align="left" colspan="1" rowspan="1">13/23 (56.5)</td><td align="left" colspan="1" rowspan="1">6/9 (66.7)</td><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">Risk stratification</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">&#160;EAU High risk</td><td align="left" colspan="1" rowspan="1">37 (94.9)</td><td align="left" colspan="1" rowspan="1">11 (91.7)</td><td align="left" colspan="1" rowspan="1">0.561</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;NCCN High risk</td><td align="left" colspan="1" rowspan="1">34 (87.2)</td><td align="left" colspan="1" rowspan="1">12 (100)</td><td align="left" colspan="1" rowspan="1">0.323</td></tr><tr><td align="left" colspan="1" rowspan="1">Neoadjuvant therapy, n (%)</td><td align="left" colspan="1" rowspan="1">9 (23.1)</td><td align="left" colspan="1" rowspan="1">0 (0)</td><td align="left" colspan="1" rowspan="1">0.094</td></tr></tbody></table><table-wrap-foot><p><italic toggle="yes">P</italic>-values for statistically significant results are highlighted in bold</p><p><italic toggle="yes">BC</italic> bladder cancer; <italic toggle="yes">BMI</italic> body mass index; <italic toggle="yes">CKD</italic> chronic kidney disease; <italic toggle="yes">Cr</italic> serum creatinine; <italic toggle="yes">eGFR</italic> estimated glomerular filtration rate; <italic toggle="yes">KSS</italic> kidney sparing surgery; <italic toggle="yes">Preop</italic> preoperative; <italic toggle="yes">TURB</italic> transurethral resection of bladder tumor; <italic toggle="yes">RNU</italic> radical nephroureterectomy; <italic toggle="yes">URS</italic> ureteroscopy; <italic toggle="yes">UTUC</italic> upper tract urothelial carcinoma</p><p>*KSS included 10 segmental ureterectomies and two endoscopic ablations</p></table-wrap-foot></table-wrap>
</p><p id="Par14">
<table-wrap id="Tab2" position="float" orientation="portrait"><label>Table 2</label><caption><p>Postoperative outcomes of solitary kidney UTUC patients undergoing RNU vs. KSS</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" colspan="1" rowspan="1">Variables</th><th align="left" colspan="1" rowspan="1">RNU<break/>(<italic toggle="yes">n</italic>&#8201;=&#8201;39)</th><th align="left" colspan="1" rowspan="1">KSS*<break/>
<italic toggle="yes">(n&#8201;=&#8201;12)</italic>
</th><th align="left" colspan="1" rowspan="1"><italic toggle="yes">P</italic> value</th></tr></thead><tbody><tr><td align="left" colspan="1" rowspan="1">Surgical technique, n (%)</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">0.460</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;Robotic</td><td align="left" colspan="1" rowspan="1">21 (53.9)</td><td align="left" colspan="1" rowspan="1">5/10 (50)</td><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">&#160;Laparoscopic</td><td align="left" colspan="1" rowspan="1">10 (25.6)</td><td align="left" colspan="1" rowspan="1">1/10 (10)</td><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">&#160;Open</td><td align="left" colspan="1" rowspan="1">8 (20.5)</td><td align="left" colspan="1" rowspan="1">4/10 (40)</td><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">Approach, n (%)</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">0.660</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;Transperitoneal</td><td align="left" colspan="1" rowspan="1">31 (79.5)</td><td align="left" colspan="1" rowspan="1">9/10 (90)</td><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">Single stage procedure, n (%)</td><td align="left" colspan="1" rowspan="1">22 (56.4)</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">Concomitant radical cystectomy, n (%)</td><td align="left" colspan="1" rowspan="1">12 (30.8)</td><td align="left" colspan="1" rowspan="1">1 (10)</td><td align="left" colspan="1" rowspan="1">0.252</td></tr><tr><td align="left" colspan="1" rowspan="1">OT, median (IQR)</td><td align="left" colspan="1" rowspan="1">244.5&#160;min (165.5-353.5)</td><td align="left" colspan="1" rowspan="1">162.5&#160;min (109.5&#8211;270)</td><td align="left" colspan="1" rowspan="1">0.102</td></tr><tr><td align="left" colspan="1" rowspan="1">EBL, median (IQR)</td><td align="left" colspan="1" rowspan="1">200 mL (100&#8211;366)</td><td align="left" colspan="1" rowspan="1">100 mL (50&#8211;100)</td><td align="left" colspan="1" rowspan="1">
<bold>0.013</bold>
</td></tr><tr><td align="left" colspan="1" rowspan="1">Bladder cuff Management, n (%)</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">0.246</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;Open extravesical excision</td><td align="left" colspan="1" rowspan="1">5/35 (14.3)</td><td align="left" colspan="1" rowspan="1">3/10 (30)</td><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">&#160;Minimally invasive transvesical</td><td align="left" colspan="1" rowspan="1">2/35 (5.7)</td><td align="left" colspan="1" rowspan="1">1/10 (10)</td><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">&#160;Minimally invasive extravesical</td><td align="left" colspan="1" rowspan="1">17/35 (48.5)</td><td align="left" colspan="1" rowspan="1">5/10 (50)</td><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">&#160;Pluck technique</td><td align="left" colspan="1" rowspan="1">1/35 (2.9)</td><td align="left" colspan="1" rowspan="1">1/10 (10)</td><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">&#160;Unroofing</td><td align="left" colspan="1" rowspan="1">1/35 (2.9)</td><td align="left" colspan="1" rowspan="1">0 (0)</td><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">&#160;Not removed</td><td align="left" colspan="1" rowspan="1">9/35 (25.7)</td><td align="left" colspan="1" rowspan="1">0 (0)</td><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">Lymph node dissection, n (%)</td><td align="left" colspan="1" rowspan="1">20 (51.3)</td><td align="left" colspan="1" rowspan="1">5/10 (50)</td><td align="left" colspan="1" rowspan="1">1</td></tr><tr><td align="left" colspan="1" rowspan="1">Intraoperative complications</td><td align="left" colspan="1" rowspan="1">2 (5.3)</td><td align="left" colspan="1" rowspan="1">1 (8.3)</td><td align="left" colspan="1" rowspan="1">1</td></tr><tr><td align="left" colspan="1" rowspan="1">30-day postop complications</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">&#160;Yes</td><td align="left" colspan="1" rowspan="1">14 (35.9)</td><td align="left" colspan="1" rowspan="1">5 (41.7)</td><td align="left" colspan="1" rowspan="1">1</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;CD&#8201;&#8805;&#8201;3</td><td align="left" colspan="1" rowspan="1">8 (20.5)</td><td align="left" colspan="1" rowspan="1">1 (8.3)</td><td align="left" colspan="1" rowspan="1">0.666</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;Readmission</td><td align="left" colspan="1" rowspan="1">4/36 (11.1)</td><td align="left" colspan="1" rowspan="1">3/11 (27.3)</td><td align="left" colspan="1" rowspan="1">0.330</td></tr><tr><td align="left" colspan="1" rowspan="1">LOS, median (IQR)</td><td align="left" colspan="1" rowspan="1">7.5 days (5&#8211;12)</td><td align="left" colspan="1" rowspan="1">3 days (2&#8211;5)</td><td align="left" colspan="1" rowspan="1">
<bold>&lt;&#8201;0.001</bold>
</td></tr><tr><td align="left" colspan="1" rowspan="1">Pathological stage, n (%)</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">0.429</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;pTa</td><td align="left" colspan="1" rowspan="1">9 (23.1)</td><td align="left" colspan="1" rowspan="1">4 (33.3)</td><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">&#160;pTis</td><td align="left" colspan="1" rowspan="1">2 (5.1)</td><td align="left" colspan="1" rowspan="1">0 (0)</td><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">&#160;pT1</td><td align="left" colspan="1" rowspan="1">6 (15.4)</td><td align="left" colspan="1" rowspan="1">3 (25)</td><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">&#160;pT2</td><td align="left" colspan="1" rowspan="1">5 (12.8)</td><td align="left" colspan="1" rowspan="1">2 (16.7)</td><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">&#160;pT3-4</td><td align="left" colspan="1" rowspan="1">17 (43.6)</td><td align="left" colspan="1" rowspan="1">2 (16.7)</td><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">Tumor Grade, n (%)</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">0.133</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;High grade</td><td align="left" colspan="1" rowspan="1">36 (92.3)</td><td align="left" colspan="1" rowspan="1">9 (75)</td><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">Positive Margins, n (%)</td><td align="left" colspan="1" rowspan="1">1 (2.6)</td><td align="left" colspan="1" rowspan="1">3 (25)</td><td align="left" colspan="1" rowspan="1">
<bold>0.038</bold>
</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;pN</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">0.156</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;pN0</td><td align="left" colspan="1" rowspan="1">23 (59)</td><td align="left" colspan="1" rowspan="1">3 (25)</td><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">&#160;&#8805;pN1</td><td align="left" colspan="1" rowspan="1">2 (5.1)</td><td align="left" colspan="1" rowspan="1">2 (16.7)</td><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">&#160;pNx</td><td align="left" colspan="1" rowspan="1">14 (35.9)</td><td align="left" colspan="1" rowspan="1">7 (58.3)</td><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">Adjuvant treatments</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">&#160;Bladder instillation</td><td align="left" colspan="1" rowspan="1">4 (10.3)</td><td align="left" colspan="1" rowspan="1">2 (16.7)</td><td align="left" colspan="1" rowspan="1">0.616</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;Systemic therapy</td><td align="left" colspan="1" rowspan="1">2/36 (5.6)</td><td align="left" colspan="1" rowspan="1">2 (16.7)</td><td align="left" colspan="1" rowspan="1">0.257</td></tr><tr><td align="left" colspan="1" rowspan="1">Postoperative Cr</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">&#160;Discharge</td><td align="left" colspan="1" rowspan="1">6&#160;mg/dL (3.45&#8211;7.81)</td><td align="left" colspan="1" rowspan="1">1.3&#160;mg/dL (1.2&#8211;1.6)</td><td align="left" colspan="1" rowspan="1">
<bold>&lt;&#8201;0.001</bold>
</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;12 months</td><td align="left" colspan="1" rowspan="1">4.1&#160;mg/dL (1.48&#8211;7.5)</td><td align="left" colspan="1" rowspan="1">1.5&#160;mg/dL (1.4&#8211;1.6)</td><td align="left" colspan="1" rowspan="1">0.074</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;Last follow-up</td><td align="left" colspan="1" rowspan="1">5.9&#160;mg/dL (2-8.8)</td><td align="left" colspan="1" rowspan="1">1.5&#160;mg/dL (0.75&#8211;1.8)</td><td align="left" colspan="1" rowspan="1">
<bold>0.009</bold>
</td></tr><tr><td align="left" colspan="1" rowspan="1">Postoperative eGFR</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">&#160;Discharge</td><td align="left" colspan="1" rowspan="1">9 mL/min/1.73m<sup>2</sup> (6.8&#8211;15.1)</td><td align="left" colspan="1" rowspan="1">50 mL/min/1.73m<sup>2</sup> (30&#8211;53)</td><td align="left" colspan="1" rowspan="1">
<bold>&lt;&#8201;0.001</bold>
</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;12 months</td><td align="left" colspan="1" rowspan="1">12.2 mL/min/1.73m<sup>2</sup> (6&#8211;44)</td><td align="left" colspan="1" rowspan="1">46 mL/min/1.73m<sup>2</sup> (32&#8211;48)</td><td align="left" colspan="1" rowspan="1">0.111</td></tr><tr><td align="left" colspan="1" rowspan="1">Last follow-up</td><td align="left" colspan="1" rowspan="1">7.5 mL/min/1.73m<sup>2</sup> (6&#8211;32)</td><td align="left" colspan="1" rowspan="1">38 mL/min/1.73m<sup>2</sup> (32&#8211;85)</td><td align="left" colspan="1" rowspan="1">
<bold>0.012</bold>
</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;&#160;&#916;eGFR</td><td align="left" colspan="1" rowspan="1">-18.1 mL/min/1.73m<sup>2</sup> (-34;1)</td><td align="left" colspan="1" rowspan="1">-2 mL/min/1.73m<sup>2</sup> (-5;21)</td><td align="left" colspan="1" rowspan="1">0.101</td></tr></tbody></table><table-wrap-foot><p><italic toggle="yes">P</italic>-values for statistically significant results are highlighted in bold</p><p><italic toggle="yes">CD</italic> Clavien-Dindo; <italic toggle="yes">Cr</italic> serum creatinine; <italic toggle="yes">EBL</italic> estimated blood loss; <italic toggle="yes">eGFR</italic> estimated glomerular filtration rate; <italic toggle="yes">KSS</italic> kidney sparing surgery; <italic toggle="yes">LOS</italic> length of stay; <italic toggle="yes">OT</italic> operative time; <italic toggle="yes">Postop</italic> postoperative; <italic toggle="yes">RNU</italic> radical nephroureterectomy; <italic toggle="yes">UTUC</italic> upper tract urothelial carcinoma</p><p>*KSS included 10 segmental ureterectomies and two endoscopic ablations</p></table-wrap-foot></table-wrap>
</p></sec><sec id="Sec8"><title>Perioperative outcomes</title><p id="Par15">Perioperative outcomes are reported in Table&#160;<xref rid="Tab2" ref-type="table">2</xref>. Robotic surgery was the most common approach (21 RNU, 53.9% vs. 5/10 KSS, 50%; <italic toggle="yes">p</italic>&#8201;=&#8201;0.460), regardless of the surgery type. A median operative time of 244.5&#160;min (IQR: 165.5&#8211;353.5), and a median EBL of 200 mL (100&#8211;366) was registered for RNU, compared to a median operative time of 162.5&#160;min (109.5&#8211;270, <italic toggle="yes">p</italic>&#8201;=&#8201;0.102), and a median EBL of 100 mL (50&#8211;100, <italic toggle="yes">p</italic>&#8201;=&#8201;0.013) when looking at KSS. Median LOS was statistically significantly longer for RNU (7.5 days, 5&#8211;12) than KSS (3 days, 2&#8211;5; <italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.001). Moreover, similar rates of any grade (RNU: 35.9% vs. KSS: 41.7%, <italic toggle="yes">p</italic>&#8201;=&#8201;1) and major (RNU: 20.5% vs. KSS: 8.3%, <italic toggle="yes">p</italic>&#8201;=&#8201;0.666) postoperative complications were observed among the two subgroups. Postoperative acute kidney injury occurred in 39 RNU patients (100%) and 2 KSS patients (16.7%), with no significant difference in terms of complications type between the subgroups (<italic toggle="yes">p</italic>&#8201;=&#8201;0.241), as depicted in Supplementary Table 1. Additionally, the analysis of postoperative functional outcomes revealed significantly higher SCr and lower eGFR at both discharge and last follow-up in patients undergoing RNU compared to KSS (all <italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.05).</p></sec><sec id="Sec9"><title>Pathological outcomes</title><p id="Par16">Among patients undergoing RNU, more than half (22, 56.4%) had muscle-invasive disease (&#8805;&#8201;pT2) on final histology, with the majority being high grade (36, 92.3%). Positive surgical margins were observed in only one patient (2.6%), and nodal involvement in two patients (5.1%). In contrast, most patients undergoing KSS had non&#8211;muscle-invasive tumors (7, 58.3%; <italic toggle="yes">p</italic>&#8201;=&#8201;0.429) but exhibited a significantly higher rate of positive surgical margins (3, 25%; <italic toggle="yes">p</italic>&#8201;=&#8201;0.038) and a comparable rate of nodal involvement (2, 16.7%; <italic toggle="yes">p</italic>&#8201;=&#8201;0.156).</p></sec><sec id="Sec10"><title>Survival analysis</title><p id="Par17">In the RNU cohort, the recurrence rate was 20.5%, while all-cause mortality and cancer-specific mortality were 12.8% and 5.1%, respectively. On the other hand, the recurrence rate was 25% (<italic toggle="yes">p</italic>&#8201;=&#8201;0.584) among patients undergoing KSS, including two bladder recurrences and one renal pelvis recurrence, with all-cause mortality and cancer-specific mortality rates of 25% (<italic toggle="yes">p</italic>&#8201;=&#8201;0.379) and 8.3% (<italic toggle="yes">p</italic>&#8201;=&#8201;1), respectively. The intended subanalyses by CKD stage and treatment type were not feasible due to the low number of events observed in each group. Therefore, survival analysis was conducted exclusively on patients undergoing RNU. At the 3-year follow-up, OS was 83.9%, CSS was 96.9%, RFS was 71.8%, and MFS was 84.4%. After 5 years post-surgery, OS was 73.4%, CSS was 83.1%, RFS was 59.9%, and MFS was 78.5%.</p></sec></sec><sec id="Sec11"><title>Discussion</title><p id="Par18">This study is the first to compare outcomes of solitary kidney UTUC patients undergoing RNU, resulting in anephric status, and KSS in a multicenter international setting. Despite the postoperative functional challenges faced by patients undergoing RNU, our findings indicate that their oncological outcomes are comparable to those reported in the existing literature. However, these results come at the cost of a higher perioperative burden, as evidenced by prolonged LOS.</p><p id="Par19">Opting for RNU in solitary kidney patients is an uncommon decision, as it inevitably leads to dialysis dependence, significantly impacting patients&#8217; quality of life. This challenge likely accounts for the paucity of data in this clinical setting, limited to case reports and small case series [<xref ref-type="bibr" rid="CR7">7</xref>, <xref ref-type="bibr" rid="CR8">8</xref>]. In contrast, the ROBUUST registry includes data on over 2,900 patients, allowing us to analyze the largest available sample size of solitary kidney patients undergoing RNU to date. Most patients in our cohort were classified as high-risk, making them eligible for KSS due to imperative indications despite their risk classification [<xref ref-type="bibr" rid="CR1">1</xref>]. However, the decision to perform RNU in such cases may have been driven by severe preoperative renal function impairment, irrespective of risk classification. Indeed, in our cohort, 25% of patients had a preoperative eGFR below 30 mL/min/1.73m<sup>2</sup>, while none of the KSS patients did, possibly explaining the preference for extirpative surgery in the former subgroup. When looking at the role of preoperative renal function in guiding surgical decision-making for solitary kidney patients with UTUC, a single-center retrospective study by Su et al. provides valuable insights on this topic. In this cohort, over half of the patients had a history of aristolochic acid exposure, which contributed to a high incidence of synchronous (3.5%) and metachronous (4.8%) bilateral UTUC. Among the patients evaluated, 29 (47.5%) underwent RNU, while 32 (52.5%) received KSS. The findings demonstrated a significant association between preoperative renal function and the choice of surgical intervention, as patients undergoing RNU had significantly worse baseline eGFR than those receiving KSS [<xref ref-type="bibr" rid="CR8">8</xref>].</p><p id="Par20">The role of preoperative renal function in UTUC patients extends beyond influencing surgical treatment choice, potentially contributing to the risk of occurrence/recurrence of UTUC in solitary kidney patients. According to Wu et al., patients with ESRD on dialysis exhibited a higher incidence of UTUC along with a greater incidence of synchronous multifocal and bilateral UTUC compared to the general population [<xref ref-type="bibr" rid="CR9">9</xref>]. Additionally, a population-based retrospective study by Kang et al. found that patients with preoperative SCr levels above 1.4&#160;mg/dL had more than a threefold increased risk of contralateral recurrence [<xref ref-type="bibr" rid="CR10">10</xref>]. Consistent with these results, laboratory findings indicated suboptimal renal function in both the study cohorts, potentially identifying a group of patients at increased risk for either primary UTUC in a solitary kidney or contralateral/homolateral UTUC recurrence. The field cancerization hypothesis provides the most plausible explanation for the increased risk of UTUC development in this cohort, suggesting that the urothelium is uniformly predisposed to malignant transformation due to shared exposure to carcinogens [<xref ref-type="bibr" rid="CR11">11</xref>]. Indeed, nephrotoxic and carcinogenic agents have been implicated in both the progression of renal disease and the neoplastic transformation of urothelial tissue [<xref ref-type="bibr" rid="CR10">10</xref>]. Therefore, prior exposure to these nephrotoxic agents by patients with UTUC and a solitary kidney, often linked to conditions such as ESRD and prolonged dialysis, could further exacerbate this risk.</p><p id="Par21">From a surgical standpoint, KSS performed via an endoscopic approach can present technical and oncological challenges [<xref ref-type="bibr" rid="CR12">12</xref>] as well as a relevant risk of stenotic sequelae [<xref ref-type="bibr" rid="CR13">13</xref>]. Similarly, complex cases (i.e. large endoluminal defects) treated with renal or pelvic resection or segmental/total ureterectomy can be highly demanding and carry a significant risk of tumor seeding due to urine spillage [<xref ref-type="bibr" rid="CR14">14</xref>]. Notably, although the difference in tumor site between the two cohorts only approached statistical significance (<italic toggle="yes">p</italic>&#8201;=&#8201;0.051), with three-fourths of KSS patients having ureteral tumors compared to only one-fourth in the RNU group, a potential clinical significance can be speculated. Thus, despite growing evidence supporting the feasibility of ureterectomy in high-risk patients [<xref ref-type="bibr" rid="CR15">15</xref>&#8211;<xref ref-type="bibr" rid="CR17">17</xref>] certain extreme scenarios necessitate RNU, even in solitary kidney patients.</p><p id="Par22">What stands out from our analysis is the high incidence of any grade and major postoperative complications, regardless of the treatment type. Among patients undergoing RNU, 35% experienced any-grade postoperative complications, while 20.5% had major complications. Conversely, previous analyses of the ROBUUST registry reported any-grade complication rates around 15%, with major complications occurring in fewer than 5% of cases [<xref ref-type="bibr" rid="CR18">18</xref>, <xref ref-type="bibr" rid="CR19">19</xref>]. Moreover, a large population-based study by Franco et al. reported an incidence of 30-day postoperative complications of around 20% for RNU [<xref ref-type="bibr" rid="CR20">20</xref>]. With regards to KSS, existing literature primarily focuses on oncological outcomes, with postoperative complications largely underreported. However, a prior ROBUUST registry analysis recorded any-grade and major complication rates of 15% and 5%, respectively [<xref ref-type="bibr" rid="CR16">16</xref>]. In comparison, the current study group showed rates of 41.7% and 8.3%, respectively.</p><p id="Par23">Notably, RNU patients in this study had a significantly longer LOS compared to those undergoing KSS. Moreover, when compared with available literature, RNU patients in our cohort demonstrated a prolonged LOS [<xref ref-type="bibr" rid="CR20">20</xref>, <xref ref-type="bibr" rid="CR21">21</xref>] whereas LOS for KSS patients remained consistent with previously reported data [<xref ref-type="bibr" rid="CR17">17</xref>]. The need for postoperative hemodialysis may partially explain the delayed discharge in the RNU subgroup. As anticipated, most of the postoperative events among patients undergoing RNU were reported as acute kidney injury (39, 100%) following kidney removal, whereas only two events were reported in patients undergoing KSS. These findings highlight the need for thorough preoperative counseling to set realistic expectations regarding complications and recovery. They also emphasize the heightened vulnerability of solitary kidney patients to postoperative renal insults, underscoring the importance of close monitoring and early intervention [<xref ref-type="bibr" rid="CR22">22</xref>, <xref ref-type="bibr" rid="CR23">23</xref>]. Thus, effective hospital management should integrate nephrology collaboration to ensure timely interventions, including dialysis when necessary, to mitigate acute renal dysfunction and long-term sequelae [<xref ref-type="bibr" rid="CR24">24</xref>].</p><p id="Par24">On the whole, oncological safety and technical feasibility should remain the primary considerations when determining the appropriate therapeutic strategy. In our cohort, patients achieved a 3-year and 5-year OS of 83.9% and 73.4%, respectively, alongside a CSS of 96.9% and 83.1% at the same time points. Survival outcomes following RNU show significant variability in the literature [<xref ref-type="bibr" rid="CR21">21</xref>, <xref ref-type="bibr" rid="CR25">25</xref>, <xref ref-type="bibr" rid="CR26">26</xref>] heavily influenced by tumor grade and stage [<xref ref-type="bibr" rid="CR27">27</xref>] but in line with those observed in our analysis. The concept of surgically induced CKD, first described by Lane et al. [<xref ref-type="bibr" rid="CR28">28</xref>] refers to the adverse effects of nephron loss following kidney surgery [<xref ref-type="bibr" rid="CR29">29</xref>]. Its association with increased mortality risk and adverse metabolic effects has been well-documented in renal cell carcinoma but remains underreported in UTUC [<xref ref-type="bibr" rid="CR30">30</xref>, <xref ref-type="bibr" rid="CR31">31</xref>]. In this context, a relationship between survival and renal function was initially proposed by Kim et al. [<xref ref-type="bibr" rid="CR31">31</xref>] and subsequently corroborated by Puri et al., who reported a progressively declining 5-year OS with worsening postoperative renal function and a significantly higher risk of all-cause mortality [<xref ref-type="bibr" rid="CR32">32</xref>]. However, a retrospective study by Su et al. comparing 29 with 32 solitary kidney patients undergoing either RNU or KSS for UTUC, respectively, reported similar oncological outcomes to our findings, with no statistically significant difference between treatment arms, and almost 10% of patients undergoing KSS ultimately requiring dialytic treatment [<xref ref-type="bibr" rid="CR8">8</xref>]. These observations underscore the complex interplay between renal damage and survival outcomes. However, no study to date has specifically examined solitary kidney patients made anephric after surgery, making direct comparisons with our findings both challenging and potentially inconclusive. On one hand, this association could be mitigated in patients receiving dialytic treatment, given the complete replacement of renal function. On the other hand, it is possible that sacrificing renal function in favor of more radical surgery may lead to reduced cancer-specific mortality in this patient group. However, the strength of our findings is likely influenced by the small sample size and the low number of observed events. In addition, we were unable to perform survival subanalyses either based on preoperative renal function or surgical intervention due to the limited number of observations. Furthermore, a causal relationship between mortality and renal function should not be assumed, as the observational design of the studies does not allow for definitive conclusions. Given the limited literature available, dedicated studies are needed to clarify the long-term oncological outcomes and to provide evidence-based guidance on optimal treatment strategies for this cohort.</p><p id="Par25">This study benefits from the use of the ROBUUST 2.0 registry, a large, multi-institutional database, enhancing the generalizability of the findings. By focusing on solitary kidney patients, the present analysis sought to address an underexplored population, helping to fill a gap in the existing literature. However, several limitations must be acknowledged. Due to the absence of this data in the dataset, we were unable to determine the indication for surgery in the included patients, as well as the reason for having a solitary kidney. Moreover, the relatively short median follow-up limited the assessment of long-term oncological outcomes and dialysis-related complications, which may have influenced cancer-specific and all-cause mortality, respectively. Additionally, the small sample size, although relatively large if considering solitary kidney patients undergoing RNU, remains modest compared to other more common clinical populations, potentially reducing the power to detect smaller but clinically meaningful differences. In addition, the number of patients undergoing KSS in our cohort prevented us from performing a dedicated subanalysis by treatment type. The study&#8217;s reliance on registry data, together with its retrospective design, introduces potential selection bias, as patients included may differ systematically from those not captured. Finally, variations in follow-up protocols could exist due to the multi-institutional nature of the dataset.</p></sec><sec id="Sec12"><title>Conclusion</title><p id="Par26">Solitary kidney patients are a vulnerable group of patients requiring careful consideration of the balance between risks and benefits in the decision-making process. These patients may experience a higher incidence of UTUC compared to the general population. Furthermore, they face a substantial perioperative burden, including high complication rates and prolonged LOS. Despite these challenges, patients undergoing RNU demonstrated favorable oncological outcomes comparable to those reported in the existing literature.</p></sec><sec id="Sec13" sec-type="supplementary-material"><title>Supplementary Information</title><p>Below is the link to the electronic supplementary material.</p><p>
<supplementary-material content-type="local-data" id="MOESM1" position="float" orientation="portrait"><media xlink:href="345_2025_5882_MOESM1_ESM.docx" position="float" orientation="portrait"><caption><p>Supplementary Material 1</p></caption></media></supplementary-material>
</p></sec></body><back><fn-group><fn><p><bold>Publisher&#8217;s Note</bold></p><p>Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p></fn></fn-group><notes notes-type="author-contribution"><title>Author contributions</title><p>Conception or design of the work: Ditonno, Antonelli.Acquisition, analysis, or interpretation of data: Ditonno, Veccia, Bignante, Wu, Wang, Abdollah, Stephens, Simone, Tuderti, Lee, Eun, Correa, De Cobelli, Ferro, Porpiglia, Amparore, Checcucci, Tufano, Contieri, Perdon&#224;, Bhanvadia, Margulis, Br&#246;nimann, Singla, Porter, Ghodoussipour, Minervini, Mari, Lambertini, Ghoreifi, Nativ, Gonzalgo, Sidhom, Sundaram, Ben-David, Eraky, Mehrazin, Yoshida, Kinoshita, Dehghanmanshadi, Rais-Bahrami, Meagher, Puri, Derweesh, Moghaddam, Djaladat, Bertolo, Autorino, Antonelli.Drafting of the manuscript: DitonnoRevising the work critically for important intellectual content: Ditonno, Veccia, Bignante, Wu, Wang, Abdollah, Stephens, Simone, Tuderti, Lee, Eun, Correa, De Cobelli, Ferro, Porpiglia, Amparore, Checcucci, Tufano, Contieri, Perdon&#224;, Bhanvadia, Margulis, Br&#246;nimann, Singla, Porter, Ghodoussipour, Minervini, Mari, Lambertini, Ghoreifi, Nativ, Gonzalgo, Sidhom, Sundaram, Ben-David, Eraky, Mehrazin, Yoshida, Kinoshita, Dehghanmanshadi, Rais-Bahrami, Meagher, Puri, Derweesh, Moghaddam, Djaladat, Bertolo, Autorino, Antonelli.Supervision: AntonelliFinal approval of the version to be published: Ditonno, Veccia, Bignante, Wu, Wang, Abdollah, Stephens, Simone, Tuderti, Lee, Eun, Correa, De Cobelli, Ferro, Porpiglia, Amparore, Checcucci, Tufano, Contieri, Perdon&#224;, Bhanvadia, Margulis, Br&#246;nimann, Singla, Porter, Ghodoussipour, Minervini, Mari, Lambertini, Ghoreifi, Nativ, Gonzalgo, Sidhom, Sundaram, Ben-David, Eraky, Mehrazin, Yoshida, Kinoshita, Dehghanmanshadi, Rais-Bahrami, Meagher, Puri, Derweesh, Moghaddam, Djaladat, Bertolo, Autorino, Antonelli.Agreement to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved: Ditonno, Veccia, Bignante, Wu, Wang, Abdollah, Stephens, Simone, Tuderti, Lee, Eun, Correa, De Cobelli, Ferro, Porpiglia, Amparore, Checcucci, Tufano, Contieri, Perdon&#224;, Bhanvadia, Margulis, Br&#246;nimann, Singla, Porter, Ghodoussipour, Minervini, Mari, Lambertini, Ghoreifi, Nativ, Gonzalgo, Sidhom, Sundaram, Ben-David, Eraky, Mehrazin, Yoshida, Kinoshita, Dehghanmanshadi, Rais-Bahrami, Meagher, Puri, Derweesh, Moghaddam, Djaladat, Bertolo, Autorino, Antonelli.All authors read and approved the final version of the manuscript.</p></notes><notes notes-type="funding-information"><title>Funding</title><p>Open access funding provided by Universit&#224; degli Studi di Verona within the CRUI-CARE Agreement. The authors have no funding to declare.</p></notes><notes notes-type="data-availability"><title>Data availability</title><p>The data sets generated during and/or analyzed during the current study are available from the corresponding author upon reasonable request.</p></notes><notes><title>Declarations</title><notes id="FPar1" notes-type="COI-statement"><title>Conflict of interest</title><p id="Par27">The authors declare no competing interests.</p></notes><notes id="FPar3"><title>Ethical approval</title><p id="Par28">This study was conducted in accordance with the principles of the Declaration of Helsinki. All participants provided informed consent before participating in the study.</p></notes></notes><ref-list id="Bib1"><title>References</title><ref id="CR1"><label>1.</label><mixed-citation publication-type="other">Masson-Lecomte A, Gontero P, Birtle A et al (2024) EAU guidelines on upper urinary tract urothelial carcinoma. Eur Urol. (Edn. presented at the EAU Annual Congress Paris 2024)</mixed-citation></ref><ref id="CR2"><label>2.</label><citation-alternatives><element-citation id="ec-CR2" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Valderr&#225;bano</surname><given-names>F</given-names></name><name name-style="western"><surname>Jofre</surname><given-names>R</given-names></name><name name-style="western"><surname>L&#243;pez-G&#243;mez</surname><given-names>JM</given-names></name></person-group><article-title>Quality of life in end-stage renal disease patients</article-title><source>Am J Kidney Dis</source><year>2001</year><volume>38</volume><issue>3</issue><fpage>443</fpage><lpage>464</lpage><pub-id pub-id-type="doi">10.1053/ajkd.2001.26824</pub-id><pub-id pub-id-type="pmid">11532675</pub-id></element-citation><mixed-citation id="mc-CR2" publication-type="journal">Valderr&#225;bano F, Jofre R, L&#243;pez-G&#243;mez JM (2001) Quality of life in end-stage renal disease patients. Am J Kidney Dis 38(3):443&#8211;464. 10.1053/ajkd.2001.26824<pub-id pub-id-type="pmid">11532675</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1053/ajkd.2001.26824</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR3"><label>3.</label><citation-alternatives><element-citation id="ec-CR3" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dindo</surname><given-names>D</given-names></name><name name-style="western"><surname>Demartines</surname><given-names>N</given-names></name><name name-style="western"><surname>Clavien</surname><given-names>PA</given-names></name></person-group><article-title>Classification of surgical complications</article-title><source>Ann Surg</source><year>2004</year><volume>240</volume><issue>2</issue><fpage>205</fpage><lpage>213</lpage><pub-id pub-id-type="doi">10.1097/01.sla.0000133083.54934.ae</pub-id><pub-id pub-id-type="pmid">15273542</pub-id><pub-id pub-id-type="pmcid">PMC1360123</pub-id></element-citation><mixed-citation id="mc-CR3" publication-type="journal">Dindo D, Demartines N, Clavien PA (2004) Classification of surgical complications. Ann Surg 240(2):205&#8211;213. 10.1097/01.sla.0000133083.54934.ae<pub-id pub-id-type="pmid">15273542</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/01.sla.0000133083.54934.ae</pub-id><pub-id pub-id-type="pmcid">PMC1360123</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR4"><label>4.</label><citation-alternatives><element-citation id="ec-CR4" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Levey</surname><given-names>AS</given-names></name><name name-style="western"><surname>Stevens</surname><given-names>LA</given-names></name><name name-style="western"><surname>Schmid</surname><given-names>CH</given-names></name><etal/></person-group><article-title>A new equation to estimate glomerular filtration rate</article-title><source>Ann Intern Med</source><year>2009</year><volume>150</volume><issue>9</issue><fpage>604</fpage><pub-id pub-id-type="doi">10.7326/0003-4819-150-9-200905050-00006</pub-id><pub-id pub-id-type="pmid">19414839</pub-id><pub-id pub-id-type="pmcid">PMC2763564</pub-id></element-citation><mixed-citation id="mc-CR4" publication-type="journal">Levey AS, Stevens LA, Schmid CH et al (2009) A new equation to estimate glomerular filtration rate. Ann Intern Med 150(9):604. 10.7326/0003-4819-150-9-200905050-00006<pub-id pub-id-type="pmid">19414839</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.7326/0003-4819-150-9-200905050-00006</pub-id><pub-id pub-id-type="pmcid">PMC2763564</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR5"><label>5.</label><citation-alternatives><element-citation id="ec-CR5" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Assel</surname><given-names>M</given-names></name><name name-style="western"><surname>Sjoberg</surname><given-names>D</given-names></name><name name-style="western"><surname>Elders</surname><given-names>A</given-names></name><etal/></person-group><article-title>Guidelines for reporting of statistics for clinical research in urology</article-title><source>Eur Urol</source><year>2019</year><volume>75</volume><issue>3</issue><fpage>358</fpage><lpage>367</lpage><pub-id pub-id-type="doi">10.1016/j.eururo.2018.12.014</pub-id><pub-id pub-id-type="pmid">30580902</pub-id><pub-id pub-id-type="pmcid">PMC6391870</pub-id></element-citation><mixed-citation id="mc-CR5" publication-type="journal">Assel M, Sjoberg D, Elders A et al (2019) Guidelines for reporting of statistics for clinical research in urology. Eur Urol 75(3):358&#8211;367. 10.1016/j.eururo.2018.12.014<pub-id pub-id-type="pmid">30580902</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.eururo.2018.12.014</pub-id><pub-id pub-id-type="pmcid">PMC6391870</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR6"><label>6.</label><citation-alternatives><element-citation id="ec-CR6" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Vickers</surname><given-names>AJ</given-names></name><name name-style="western"><surname>Assel</surname><given-names>MJ</given-names></name><name name-style="western"><surname>Sjoberg</surname><given-names>DD</given-names></name><etal/></person-group><article-title>Guidelines for reporting of figures and tables for clinical research in urology</article-title><source>Eur Urol</source><year>2020</year><volume>78</volume><issue>1</issue><fpage>97</fpage><lpage>109</lpage><pub-id pub-id-type="doi">10.1016/j.eururo.2020.04.048</pub-id><pub-id pub-id-type="pmid">32451178</pub-id></element-citation><mixed-citation id="mc-CR6" publication-type="journal">Vickers AJ, Assel MJ, Sjoberg DD et al (2020) Guidelines for reporting of figures and tables for clinical research in urology. Eur Urol 78(1):97&#8211;109. 10.1016/j.eururo.2020.04.048<pub-id pub-id-type="pmid">32451178</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.eururo.2020.04.048</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR7"><label>7.</label><citation-alternatives><element-citation id="ec-CR7" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>&#214;zveren</surname><given-names>B</given-names></name><name name-style="western"><surname>T&#252;rkeri</surname><given-names>L</given-names></name></person-group><article-title>Simultaneous robot-assisted radical cystoprostatectomy and nephroureterectomy in a patient with multifocal invasive urothelial carcinoma and previous contralateral nephroureterectomy</article-title><source>J Robot Surg</source><year>2013</year><volume>7</volume><issue>4</issue><fpage>393</fpage><lpage>396</lpage><pub-id pub-id-type="doi">10.1007/s11701-012-0381-0</pub-id><pub-id pub-id-type="pmid">27001880</pub-id></element-citation><mixed-citation id="mc-CR7" publication-type="journal">&#214;zveren B, T&#252;rkeri L (2013) Simultaneous robot-assisted radical cystoprostatectomy and nephroureterectomy in a patient with multifocal invasive urothelial carcinoma and previous contralateral nephroureterectomy. J Robot Surg 7(4):393&#8211;396. 10.1007/s11701-012-0381-0<pub-id pub-id-type="pmid">27001880</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s11701-012-0381-0</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR8"><label>8.</label><citation-alternatives><element-citation id="ec-CR8" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Su</surname><given-names>X</given-names></name><name name-style="western"><surname>Fang</surname><given-names>D</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>L</given-names></name><etal/></person-group><article-title>Treatment strategies for upper tract urothelial carcinoma (UTUC) of a solitary kidney: a single-institutional analysis of 61 cases</article-title><source>Int Urol Nephrol</source><year>2016</year><volume>48</volume><issue>10</issue><fpage>1601</fpage><lpage>1608</lpage><pub-id pub-id-type="doi">10.1007/s11255-016-1353-5</pub-id><pub-id pub-id-type="pmid">27376898</pub-id></element-citation><mixed-citation id="mc-CR8" publication-type="journal">Su X, Fang D, Zhang L et al (2016) Treatment strategies for upper tract urothelial carcinoma (UTUC) of a solitary kidney: a single-institutional analysis of 61 cases. Int Urol Nephrol 48(10):1601&#8211;1608. 10.1007/s11255-016-1353-5<pub-id pub-id-type="pmid">27376898</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s11255-016-1353-5</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR9"><label>9.</label><citation-alternatives><element-citation id="ec-CR9" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wu</surname><given-names>CF</given-names></name><name name-style="western"><surname>Chang</surname><given-names>PL</given-names></name><name name-style="western"><surname>Chen</surname><given-names>CS</given-names></name><name name-style="western"><surname>Chuang</surname><given-names>CK</given-names></name><name name-style="western"><surname>Weng</surname><given-names>HH</given-names></name><name name-style="western"><surname>Pang</surname><given-names>ST</given-names></name></person-group><article-title>The outcome of patients on Dialysis with upper urinary tract transitional cell carcinoma</article-title><source>J Urol</source><year>2006</year><volume>176</volume><issue>2</issue><fpage>477</fpage><lpage>481</lpage><pub-id pub-id-type="doi">10.1016/j.juro.2006.03.099</pub-id><pub-id pub-id-type="pmid">16813872</pub-id></element-citation><mixed-citation id="mc-CR9" publication-type="journal">Wu CF, Chang PL, Chen CS, Chuang CK, Weng HH, Pang ST (2006) The outcome of patients on Dialysis with upper urinary tract transitional cell carcinoma. J Urol 176(2):477&#8211;481. 10.1016/j.juro.2006.03.099<pub-id pub-id-type="pmid">16813872</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.juro.2006.03.099</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR10"><label>10.</label><citation-alternatives><element-citation id="ec-CR10" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kang</surname><given-names>CH</given-names></name><name name-style="western"><surname>Yu</surname><given-names>TJ</given-names></name><name name-style="western"><surname>Hsieh</surname><given-names>HH</given-names></name><etal/></person-group><article-title>The development of bladder tumors and contralateral upper urinary tract tumors after primary transitional cell carcinoma of the upper urinary tract</article-title><source>Cancer</source><year>2003</year><volume>98</volume><issue>8</issue><fpage>1620</fpage><lpage>1626</lpage><pub-id pub-id-type="doi">10.1002/cncr.11691</pub-id><pub-id pub-id-type="pmid">14534877</pub-id></element-citation><mixed-citation id="mc-CR10" publication-type="journal">Kang CH, Yu TJ, Hsieh HH et al (2003) The development of bladder tumors and contralateral upper urinary tract tumors after primary transitional cell carcinoma of the upper urinary tract. Cancer 98(8):1620&#8211;1626. 10.1002/cncr.11691<pub-id pub-id-type="pmid">14534877</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/cncr.11691</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR11"><label>11.</label><citation-alternatives><element-citation id="ec-CR11" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jones</surname><given-names>TD</given-names></name><name name-style="western"><surname>Wang</surname><given-names>M</given-names></name><name name-style="western"><surname>Eble</surname><given-names>JN</given-names></name><etal/></person-group><article-title>Molecular evidence supporting field effect in urothelial carcinogenesis</article-title><source>Clin Cancer Res</source><year>2005</year><volume>11</volume><issue>18</issue><fpage>6512</fpage><lpage>6519</lpage><pub-id pub-id-type="doi">10.1158/1078-0432.CCR-05-0891</pub-id><pub-id pub-id-type="pmid">16166427</pub-id></element-citation><mixed-citation id="mc-CR11" publication-type="journal">Jones TD, Wang M, Eble JN et al (2005) Molecular evidence supporting field effect in urothelial carcinogenesis. Clin Cancer Res 11(18):6512&#8211;6519. 10.1158/1078-0432.CCR-05-0891<pub-id pub-id-type="pmid">16166427</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1158/1078-0432.CCR-05-0891</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR12"><label>12.</label><citation-alternatives><element-citation id="ec-CR12" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Raman</surname><given-names>J</given-names></name><name name-style="western"><surname>Shore</surname><given-names>ND</given-names></name></person-group><article-title>Management of Low-grade upper tract urothelial carcinoma: an unmet need</article-title><source>Rev Urol</source><year>2020</year><volume>22</volume><issue>1</issue><fpage>1</fpage><lpage>8</lpage><pub-id pub-id-type="pmid">32523465</pub-id><pub-id pub-id-type="pmcid">PMC7265178</pub-id></element-citation><mixed-citation id="mc-CR12" publication-type="journal">Raman J, Shore ND (2020) Management of Low-grade upper tract urothelial carcinoma: an unmet need. Rev Urol 22(1):1&#8211;8<pub-id pub-id-type="pmid">32523465</pub-id><pub-id pub-id-type="pmcid">PMC7265178</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR13"><label>13.</label><citation-alternatives><element-citation id="ec-CR13" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Linehan</surname><given-names>J</given-names></name><name name-style="western"><surname>Schoenberg</surname><given-names>M</given-names></name><name name-style="western"><surname>Seltzer</surname><given-names>E</given-names></name><name name-style="western"><surname>Thacker</surname><given-names>K</given-names></name><name name-style="western"><surname>Smith</surname><given-names>AB</given-names></name></person-group><article-title>Complications associated with ureteroscopic management of upper tract urothelial carcinoma</article-title><source>Urology</source><year>2021</year><volume>147</volume><fpage>87</fpage><lpage>95</lpage><pub-id pub-id-type="doi">10.1016/j.urology.2020.09.036</pub-id><pub-id pub-id-type="pmid">33031842</pub-id></element-citation><mixed-citation id="mc-CR13" publication-type="journal">Linehan J, Schoenberg M, Seltzer E, Thacker K, Smith AB (2021) Complications associated with ureteroscopic management of upper tract urothelial carcinoma. Urology 147:87&#8211;95. 10.1016/j.urology.2020.09.036<pub-id pub-id-type="pmid">33031842</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.urology.2020.09.036</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR14"><label>14.</label><citation-alternatives><element-citation id="ec-CR14" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Saini</surname><given-names>S</given-names></name><name name-style="western"><surname>Deveshwar</surname><given-names>SP</given-names></name><name name-style="western"><surname>Hemal</surname><given-names>AK</given-names></name></person-group><article-title>Narrative review of nephron-sparing surgical management of upper tract urothelial carcinoma: is there a role for distal ureterectomy, segmental ureterectomy, and partial nephrectomy</article-title><source>Transl Androl Urol</source><year>2024</year><volume>13</volume><issue>1</issue><fpage>156</fpage><lpage>164</lpage><pub-id pub-id-type="doi">10.21037/tau-23-123</pub-id><pub-id pub-id-type="pmid">38404550</pub-id><pub-id pub-id-type="pmcid">PMC10891386</pub-id></element-citation><mixed-citation id="mc-CR14" publication-type="journal">Saini S, Deveshwar SP, Hemal AK (2024) Narrative review of nephron-sparing surgical management of upper tract urothelial carcinoma: is there a role for distal ureterectomy, segmental ureterectomy, and partial nephrectomy. Transl Androl Urol 13(1):156&#8211;164. 10.21037/tau-23-123<pub-id pub-id-type="pmid">38404550</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.21037/tau-23-123</pub-id><pub-id pub-id-type="pmcid">PMC10891386</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR15"><label>15.</label><citation-alternatives><element-citation id="ec-CR15" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Masson-Lecomte</surname><given-names>A</given-names></name><name name-style="western"><surname>Vaillant</surname><given-names>V</given-names></name><name name-style="western"><surname>Roumigui&#233;</surname><given-names>M</given-names></name><etal/></person-group><article-title>Oncological outcomes of distal ureterectomy for High-Risk urothelial carcinoma: A multicenter study by the French bladder cancer committee</article-title><source>Cancers 2022</source><year>2022</year><volume>14</volume><issue>21</issue><fpage>5452</fpage><pub-id pub-id-type="doi">10.3390/CANCERS14215452</pub-id><pub-id pub-id-type="pmcid">PMC9656759</pub-id><pub-id pub-id-type="pmid">36358870</pub-id></element-citation><mixed-citation id="mc-CR15" publication-type="journal">Masson-Lecomte A, Vaillant V, Roumigui&#233; M et al (2022) Oncological outcomes of distal ureterectomy for High-Risk urothelial carcinoma: A multicenter study by the French bladder cancer committee. Cancers 2022 14(21):5452. 10.3390/CANCERS14215452<pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/cancers14215452</pub-id><pub-id pub-id-type="pmcid">PMC9656759</pub-id><pub-id pub-id-type="pmid">36358870</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR16"><label>16.</label><citation-alternatives><element-citation id="ec-CR16" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ditonno</surname><given-names>F</given-names></name><name name-style="western"><surname>Franco</surname><given-names>A</given-names></name><name name-style="western"><surname>Veccia</surname><given-names>A</given-names></name><etal/></person-group><article-title>Robotic distal ureterectomy for high-risk distal ureteral urothelial carcinoma: a retrospective multicenter comparative analysis (roBUUST 2.0 collaborative group)</article-title><source>Minerva Urol Nephrol</source><year>2024</year><volume>76</volume><issue>3</issue><fpage>331</fpage><lpage>339</lpage><pub-id pub-id-type="doi">10.23736/S2724-6051.24.05737-9</pub-id><pub-id pub-id-type="pmid">38920013</pub-id></element-citation><mixed-citation id="mc-CR16" publication-type="journal">Ditonno F, Franco A, Veccia A et al (2024) Robotic distal ureterectomy for high-risk distal ureteral urothelial carcinoma: a retrospective multicenter comparative analysis (roBUUST 2.0 collaborative group). Minerva Urol Nephrol 76(3):331&#8211;339. 10.23736/S2724-6051.24.05737-9<pub-id pub-id-type="pmid">38920013</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.23736/S2724-6051.24.05737-9</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR17"><label>17.</label><citation-alternatives><element-citation id="ec-CR17" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Campi</surname><given-names>R</given-names></name><name name-style="western"><surname>Cotte</surname><given-names>J</given-names></name><name name-style="western"><surname>Sessa</surname><given-names>F</given-names></name><etal/></person-group><article-title>Robotic radical nephroureterectomy and segmental ureterectomy for upper tract urothelial carcinoma: a multi-institutional experience</article-title><source>World J Urol</source><year>2019</year><volume>37</volume><issue>11</issue><fpage>2303</fpage><lpage>2311</lpage><pub-id pub-id-type="doi">10.1007/s00345-019-02790-y</pub-id><pub-id pub-id-type="pmid">31062121</pub-id></element-citation><mixed-citation id="mc-CR17" publication-type="journal">Campi R, Cotte J, Sessa F et al (2019) Robotic radical nephroureterectomy and segmental ureterectomy for upper tract urothelial carcinoma: a multi-institutional experience. World J Urol 37(11):2303&#8211;2311. 10.1007/s00345-019-02790-y<pub-id pub-id-type="pmid">31062121</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s00345-019-02790-y</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR18"><label>18.</label><citation-alternatives><element-citation id="ec-CR18" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yong</surname><given-names>C</given-names></name><name name-style="western"><surname>Slaven</surname><given-names>JE</given-names></name><name name-style="western"><surname>Wu</surname><given-names>Z</given-names></name><etal/></person-group><article-title>The impact of bladder cuff excision on outcomes after nephroureterectomy for upper tract urothelial carcinoma: an analysis of the ROBUUST 2.0 registry</article-title><source>Urologic Oncology: Seminars Original Investigations</source><year>2024</year><volume>42</volume><issue>11</issue><fpage>373</fpage><pub-id pub-id-type="doi">10.1016/j.urolonc.2024.06.001</pub-id><pub-id pub-id-type="pmid">39112105</pub-id></element-citation><mixed-citation id="mc-CR18" publication-type="journal">Yong C, Slaven JE, Wu Z et al (2024) The impact of bladder cuff excision on outcomes after nephroureterectomy for upper tract urothelial carcinoma: an analysis of the ROBUUST 2.0 registry. Urologic Oncology: Seminars Original Investigations 42(11):373. 10.1016/j.urolonc.2024.06.001<pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.urolonc.2024.06.001</pub-id><pub-id pub-id-type="pmid">39112105</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR19"><label>19.</label><citation-alternatives><element-citation id="ec-CR19" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ditonno</surname><given-names>F</given-names></name><name name-style="western"><surname>Franco</surname><given-names>A</given-names></name><name name-style="western"><surname>Wu</surname><given-names>Z</given-names></name><etal/></person-group><article-title>Robot-assisted nephroureterectomy: surgical and mid&#8208;term oncological outcomes in over 1100 patients (ROBUUST 2.0 collaborative group)</article-title><source>BJU Int</source><year>2024</year><volume>134</volume><issue>6</issue><fpage>967</fpage><lpage>975</lpage><pub-id pub-id-type="doi">10.1111/bju.16526</pub-id><pub-id pub-id-type="pmid">39263834</pub-id></element-citation><mixed-citation id="mc-CR19" publication-type="journal">Ditonno F, Franco A, Wu Z et al (2024) Robot-assisted nephroureterectomy: surgical and mid&#8208;term oncological outcomes in over 1100 patients (ROBUUST 2.0 collaborative group). BJU Int 134(6):967&#8211;975. 10.1111/bju.16526<pub-id pub-id-type="pmid">39263834</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/bju.16526</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR20"><label>20.</label><citation-alternatives><element-citation id="ec-CR20" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Franco</surname><given-names>A</given-names></name><name name-style="western"><surname>Ditonno</surname><given-names>F</given-names></name><name name-style="western"><surname>Manfredi</surname><given-names>C</given-names></name><etal/></person-group><article-title>Open versus minimally invasive nephroureterectomy: contemporary analysis from a wide National Population-Based database</article-title><source>Ann Surg Oncol</source><year>2024</year><volume>31</volume><issue>10</issue><fpage>7212</fpage><lpage>7219</lpage><pub-id pub-id-type="doi">10.1245/s10434-024-15565-6</pub-id><pub-id pub-id-type="pmid">38879671</pub-id></element-citation><mixed-citation id="mc-CR20" publication-type="journal">Franco A, Ditonno F, Manfredi C et al (2024) Open versus minimally invasive nephroureterectomy: contemporary analysis from a wide National Population-Based database. Ann Surg Oncol 31(10):7212&#8211;7219. 10.1245/s10434-024-15565-6<pub-id pub-id-type="pmid">38879671</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1245/s10434-024-15565-6</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR21"><label>21.</label><citation-alternatives><element-citation id="ec-CR21" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gabriel</surname><given-names>PE</given-names></name><name name-style="western"><surname>Pinar</surname><given-names>U</given-names></name><name name-style="western"><surname>Lenfant</surname><given-names>L</given-names></name><etal/></person-group><article-title>Perioperative, renal function and oncological outcomes of robot-assisted radical nephroureterectomy for patients with upper tract urothelial carcinoma</article-title><source>World J Urol</source><year>2023</year><volume>41</volume><issue>11</issue><fpage>3001</fpage><lpage>3007</lpage><pub-id pub-id-type="doi">10.1007/s00345-023-04590-x</pub-id><pub-id pub-id-type="pmid">37676283</pub-id></element-citation><mixed-citation id="mc-CR21" publication-type="journal">Gabriel PE, Pinar U, Lenfant L et al (2023) Perioperative, renal function and oncological outcomes of robot-assisted radical nephroureterectomy for patients with upper tract urothelial carcinoma. World J Urol 41(11):3001&#8211;3007. 10.1007/s00345-023-04590-x<pub-id pub-id-type="pmid">37676283</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s00345-023-04590-x</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR22"><label>22.</label><citation-alternatives><element-citation id="ec-CR22" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Coca</surname><given-names>SG</given-names></name><name name-style="western"><surname>Yusuf</surname><given-names>B</given-names></name><name name-style="western"><surname>Shlipak</surname><given-names>MG</given-names></name><name name-style="western"><surname>Garg</surname><given-names>AX</given-names></name><name name-style="western"><surname>Parikh</surname><given-names>CR</given-names></name></person-group><article-title>Long-term risk of mortality and other adverse outcomes after acute kidney injury: A systematic review and Meta-analysis</article-title><source>Am J Kidney Dis</source><year>2009</year><volume>53</volume><issue>6</issue><fpage>961</fpage><lpage>973</lpage><pub-id pub-id-type="doi">10.1053/j.ajkd.2008.11.034</pub-id><pub-id pub-id-type="pmid">19346042</pub-id><pub-id pub-id-type="pmcid">PMC2726041</pub-id></element-citation><mixed-citation id="mc-CR22" publication-type="journal">Coca SG, Yusuf B, Shlipak MG, Garg AX, Parikh CR (2009) Long-term risk of mortality and other adverse outcomes after acute kidney injury: A systematic review and Meta-analysis. Am J Kidney Dis 53(6):961&#8211;973. 10.1053/j.ajkd.2008.11.034<pub-id pub-id-type="pmid">19346042</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1053/j.ajkd.2008.11.034</pub-id><pub-id pub-id-type="pmcid">PMC2726041</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR23"><label>23.</label><citation-alternatives><element-citation id="ec-CR23" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hobson</surname><given-names>C</given-names></name><name name-style="western"><surname>Ozrazgat-Baslanti</surname><given-names>T</given-names></name><name name-style="western"><surname>Kuxhausen</surname><given-names>A</given-names></name><etal/></person-group><article-title>Cost and mortality associated with postoperative acute kidney injury</article-title><source>Ann Surg</source><year>2015</year><volume>261</volume><issue>6</issue><fpage>1207</fpage><lpage>1214</lpage><pub-id pub-id-type="doi">10.1097/SLA.0000000000000732</pub-id><pub-id pub-id-type="pmid">24887982</pub-id><pub-id pub-id-type="pmcid">PMC4247993</pub-id></element-citation><mixed-citation id="mc-CR23" publication-type="journal">Hobson C, Ozrazgat-Baslanti T, Kuxhausen A et al (2015) Cost and mortality associated with postoperative acute kidney injury. Ann Surg 261(6):1207&#8211;1214. 10.1097/SLA.0000000000000732<pub-id pub-id-type="pmid">24887982</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/SLA.0000000000000732</pub-id><pub-id pub-id-type="pmcid">PMC4247993</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR24"><label>24.</label><citation-alternatives><element-citation id="ec-CR24" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mehta</surname><given-names>RL</given-names></name><name name-style="western"><surname>McDonald</surname><given-names>B</given-names></name><name name-style="western"><surname>Gabbai</surname><given-names>F</given-names></name><etal/></person-group><article-title>Nephrology consultation in acute renal failure</article-title><source>Am J Med</source><year>2002</year><volume>113</volume><issue>6</issue><fpage>456</fpage><lpage>461</lpage><pub-id pub-id-type="doi">10.1016/S0002-9343(02)01230-5</pub-id><pub-id pub-id-type="pmid">12427493</pub-id></element-citation><mixed-citation id="mc-CR24" publication-type="journal">Mehta RL, McDonald B, Gabbai F et al (2002) Nephrology consultation in acute renal failure. Am J Med 113(6):456&#8211;461. 10.1016/S0002-9343(02)01230-5<pub-id pub-id-type="pmid">12427493</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/s0002-9343(02)01230-5</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR25"><label>25.</label><citation-alternatives><element-citation id="ec-CR25" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Veeratterapillay</surname><given-names>R</given-names></name><name name-style="western"><surname>Geraghty</surname><given-names>R</given-names></name><name name-style="western"><surname>Pandian</surname><given-names>R</given-names></name><etal/></person-group><article-title>Ten-year survival outcomes after radical nephroureterectomy with a risk&#8208;stratified approach using prior diagnostic ureteroscopy: a single&#8208;institution observational retrospective cohort study</article-title><source>BJU Int</source><year>2022</year><volume>129</volume><issue>6</issue><fpage>744</fpage><lpage>751</lpage><pub-id pub-id-type="doi">10.1111/bju.15627</pub-id><pub-id pub-id-type="pmid">34726325</pub-id></element-citation><mixed-citation id="mc-CR25" publication-type="journal">Veeratterapillay R, Geraghty R, Pandian R et al (2022) Ten-year survival outcomes after radical nephroureterectomy with a risk&#8208;stratified approach using prior diagnostic ureteroscopy: a single&#8208;institution observational retrospective cohort study. BJU Int 129(6):744&#8211;751. 10.1111/bju.15627<pub-id pub-id-type="pmid">34726325</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/bju.15627</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR26"><label>26.</label><citation-alternatives><element-citation id="ec-CR26" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Grossmann</surname><given-names>NC</given-names></name><name name-style="western"><surname>Soria</surname><given-names>F</given-names></name><name name-style="western"><surname>Juvet</surname><given-names>T</given-names></name><etal/></person-group><article-title>Comparing oncological and perioperative outcomes of open versus laparoscopic versus robotic radical nephroureterectomy for the treatment of upper tract urothelial carcinoma: A multicenter, multinational, propensity Score-Matched analysis</article-title><source>Cancers (Basel)</source><year>2023</year><volume>15</volume><issue>5</issue><fpage>1409</fpage><pub-id pub-id-type="doi">10.3390/cancers15051409</pub-id><pub-id pub-id-type="pmid">36900201</pub-id><pub-id pub-id-type="pmcid">PMC10000228</pub-id></element-citation><mixed-citation id="mc-CR26" publication-type="journal">Grossmann NC, Soria F, Juvet T et al (2023) Comparing oncological and perioperative outcomes of open versus laparoscopic versus robotic radical nephroureterectomy for the treatment of upper tract urothelial carcinoma: A multicenter, multinational, propensity Score-Matched analysis. Cancers (Basel) 15(5):1409. 10.3390/cancers15051409<pub-id pub-id-type="pmid">36900201</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/cancers15051409</pub-id><pub-id pub-id-type="pmcid">PMC10000228</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR27"><label>27.</label><citation-alternatives><element-citation id="ec-CR27" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rosiello</surname><given-names>G</given-names></name><name name-style="western"><surname>Palumbo</surname><given-names>C</given-names></name><name name-style="western"><surname>Knipper</surname><given-names>S</given-names></name><etal/></person-group><article-title>Contemporary conditional cancer-specific survival after radical nephroureterectomy in patients with nonmetastatic urothelial carcinoma of upper urinary tract</article-title><source>J Surg Oncol</source><year>2020</year><volume>121</volume><issue>7</issue><fpage>1154</fpage><lpage>1161</lpage><pub-id pub-id-type="doi">10.1002/jso.25877</pub-id><pub-id pub-id-type="pmid">32107785</pub-id></element-citation><mixed-citation id="mc-CR27" publication-type="journal">Rosiello G, Palumbo C, Knipper S et al (2020) Contemporary conditional cancer-specific survival after radical nephroureterectomy in patients with nonmetastatic urothelial carcinoma of upper urinary tract. J Surg Oncol 121(7):1154&#8211;1161. 10.1002/jso.25877<pub-id pub-id-type="pmid">32107785</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/jso.25877</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR28"><label>28.</label><citation-alternatives><element-citation id="ec-CR28" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lane</surname><given-names>BR</given-names></name><name name-style="western"><surname>Demirjian</surname><given-names>S</given-names></name><name name-style="western"><surname>Derweesh</surname><given-names>IH</given-names></name><etal/></person-group><article-title>Survival and functional stability in chronic kidney disease due to surgical removal of nephrons: importance of the new baseline glomerular filtration rate</article-title><source>Eur Urol</source><year>2015</year><volume>68</volume><issue>6</issue><fpage>996</fpage><lpage>1003</lpage><pub-id pub-id-type="doi">10.1016/j.eururo.2015.04.043</pub-id><pub-id pub-id-type="pmid">26012710</pub-id></element-citation><mixed-citation id="mc-CR28" publication-type="journal">Lane BR, Demirjian S, Derweesh IH et al (2015) Survival and functional stability in chronic kidney disease due to surgical removal of nephrons: importance of the new baseline glomerular filtration rate. Eur Urol 68(6):996&#8211;1003. 10.1016/j.eururo.2015.04.043<pub-id pub-id-type="pmid">26012710</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.eururo.2015.04.043</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR29"><label>29.</label><citation-alternatives><element-citation id="ec-CR29" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tafuri</surname><given-names>A</given-names></name><name name-style="western"><surname>Marchioni</surname><given-names>M</given-names></name><name name-style="western"><surname>Cerrato</surname><given-names>C</given-names></name><etal/></person-group><article-title>Changes in renal function after nephroureterectomy for upper urinary tract carcinoma: analysis of a large multicenter cohort (Radical nephroureterectomy outcomes (RaNeO) research Consortium)</article-title><source>World J Urol</source><year>2022</year><volume>40</volume><issue>11</issue><fpage>2771</fpage><lpage>2779</lpage><pub-id pub-id-type="doi">10.1007/s00345-022-04156-3</pub-id><pub-id pub-id-type="pmid">36203101</pub-id><pub-id pub-id-type="pmcid">PMC9617815</pub-id></element-citation><mixed-citation id="mc-CR29" publication-type="journal">Tafuri A, Marchioni M, Cerrato C et al (2022) Changes in renal function after nephroureterectomy for upper urinary tract carcinoma: analysis of a large multicenter cohort (Radical nephroureterectomy outcomes (RaNeO) research Consortium). World J Urol 40(11):2771&#8211;2779. 10.1007/s00345-022-04156-3<pub-id pub-id-type="pmid">36203101</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s00345-022-04156-3</pub-id><pub-id pub-id-type="pmcid">PMC9617815</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR30"><label>30.</label><citation-alternatives><element-citation id="ec-CR30" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nguyen</surname><given-names>MV</given-names></name><name name-style="western"><surname>Walia</surname><given-names>A</given-names></name><name name-style="western"><surname>Saidian</surname><given-names>A</given-names></name><etal/></person-group><article-title>Impact of worsening surgically induced chronic kidney disease (CKD-S) in preoperative CKD&#8208;na&#239;ve patients on survival in renal cell carcinoma</article-title><source>BJU Int</source><year>2023</year><volume>131</volume><issue>2</issue><fpage>219</fpage><lpage>226</lpage><pub-id pub-id-type="doi">10.1111/bju.15861</pub-id><pub-id pub-id-type="pmid">35876044</pub-id></element-citation><mixed-citation id="mc-CR30" publication-type="journal">Nguyen MV, Walia A, Saidian A et al (2023) Impact of worsening surgically induced chronic kidney disease (CKD-S) in preoperative CKD&#8208;na&#239;ve patients on survival in renal cell carcinoma. BJU Int 131(2):219&#8211;226. 10.1111/bju.15861<pub-id pub-id-type="pmid">35876044</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/bju.15861</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR31"><label>31.</label><citation-alternatives><element-citation id="ec-CR31" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kim</surname><given-names>TH</given-names></name><name name-style="western"><surname>Sung</surname><given-names>HH</given-names></name><name name-style="western"><surname>Oh</surname><given-names>JJ</given-names></name><etal/></person-group><article-title>Clinical implication of preoperative renal function on oncological outcomes in patients with upper tract urothelial carcinoma after radical nephroureterectomy</article-title><source>Biomedicines</source><year>2022</year><volume>10</volume><issue>6</issue><fpage>1340</fpage><pub-id pub-id-type="doi">10.3390/biomedicines10061340</pub-id><pub-id pub-id-type="pmid">35740362</pub-id><pub-id pub-id-type="pmcid">PMC9220201</pub-id></element-citation><mixed-citation id="mc-CR31" publication-type="journal">Kim TH, Sung HH, Oh JJ et al (2022) Clinical implication of preoperative renal function on oncological outcomes in patients with upper tract urothelial carcinoma after radical nephroureterectomy. Biomedicines 10(6):1340. 10.3390/biomedicines10061340<pub-id pub-id-type="pmid">35740362</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/biomedicines10061340</pub-id><pub-id pub-id-type="pmcid">PMC9220201</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR32"><label>32.</label><mixed-citation publication-type="other">Puri D, Meagher MF, Wu Z et al (2024) The impact of post-nephroureterectomy surgically induced chronic kidney disease on survival outcomes. BJU Int. 10.1111/bju.16569<pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/bju.16569</pub-id><pub-id pub-id-type="pmid">39663586</pub-id></mixed-citation></ref></ref-list></back></article>
        
    </metadata>
</record>
    </GetRecord>

</OAI-PMH>